

PCTWO  INTELLECTUAL PROPI
International Bi

INTERNATIONAL APPLICATION PUBLISHED UNDER

WO 9600503A1

(51) International Patent Classification ⁶ :A16K 38/00, C07K 1/00, 7/06, 7/08, 7/10,
C12Q 1/00, 1/37

A1

(11) International Publication Number:

WO 96/00503

(43) International Publication Date:

11 January 1996 (11.01.96)

(21) International Application Number: PCT/US95/08156

(22) International Filing Date: 7 June 1995 (07.06.95)

(30) Priority Data:

267,092	28 June 1994 (28.06.94)	US
404,833	15 March 1995 (15.03.95)	US

(60) Parent Applications or Grants

(63) Related by Continuation

US	404,833 (CIP)
Filed on	15 March 1995 (15.03.95)
US	267,092 (CIP)
Filed on	28 June 1994 (28.06.94)

(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

Published*With international search report.
With amended claims.***Date of publication of the amended claims:**

22 February 1996 (22.02.96)

(72) Inventors; and

(75) Inventors/Applicants (for US only): DeFEO-JONES, Deborah [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). FENG, Dong-Mei [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). GARSKY, Victor, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065

(54) Title: NOVEL PEPTIDES

(57) Abstract

Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity *in vitro* and *in vivo*. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

AMENDED CLAIMS

[received by the International Bureau on 1 January 1996 (01.01.96);
original claim 1 amended; remaining claims unchanged (1 page)]

1. An oligopeptide, not including Semenogelin I and II,
that comprises a sequence of amino acids that is recognized and
selectively proteolytically cleaved by free prostate specific antigen.
2. The oligopeptide according to Claim 1 wherein the
sequence of amino acids is
- a) AsnLysIleSerTyrGln|Ser (SEQ.ID.NO.: 13),
- b) LysIleSerTyrGln|Ser (SEQ.ID.NO.: 14),
- c) GlyGluAsnGlyValGlnLysAspValSerGlnXaaSerIleTyr|SerGlnThrGlu
(SEQ.ID.NO.: 15),
- d) GlyLysGlyIleSerSerGlnTyr|SerAsnThrGluGluArgLeu
(SEQ.ID.NO.: 2),
- e) AsnLysIleSerTyrTyr|Ser (SEQ.ID.NO.: 127),
- f) AsnLysAlaSerTyrGln|Ser (SEQ.ID.NO.: 128),
- g) SerTyrGln|SerSer (SEQ.ID.NO.: 129);
- h) LysTyrGln|SerSer (SEQ.ID.NO.: 140); or
- i) hArgTyrGln|SerSer (SEQ.ID.NO.: 141);
- wherein hArg is homoarginine and Xaa is any natural amino acid.

3. The oligopeptide according to Claim 2 wherein the
sequence of amino acids is



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A16K 38/00, C07K 1/00, 7/06, 7/08, 7/10, C12Q 1/00, 1/37		A1	(11) International Publication Number: WO 96/00503
			(43) International Publication Date: 11 January 1996 (11.01.96)
(21) International Application Number: PCT/US95/08156			(US). JONES, Raymond, E. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). OLIFF, Allen, I. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; Patent Dept., 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ. European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(22) International Filing Date: 7 June 1995 (07.06.95)			
(30) Priority Data: 267,092 28 June 1994 (28.06.94) US 404,833 15 March 1995 (15.03.95) US			
(60) Parent Applications or Grants (63) Related by Continuation US 404,833 (CIP) Filed on 15 March 1995 (15.03.95) US 267,092 (CIP) Filed on 28 June 1994 (28.06.94)			
(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DeFEO-JONES, Deborah [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US); FENG, Dong-Mei [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). GARSKY, Victor, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065			
(54) Title: NOVEL PEPTIDES			
(57) Abstract Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity <i>in vitro</i> and <i>in vivo</i> . Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

TITLE OF THE INVENTION
NOVEL PEPTIDES

RELATED APPLICATION

5 The present patent application is a Continuation-in-Part application of copending application Serial No. 08/404,833, filed March 15, 1995, which itself is a Continuation-in-Part application of copending application Serial No. 08/267,092, filed June 28, 1994.

10 BACKGROUND OF THE INVENTION

 In 1994 cancer of the prostate gland is expected to be diagnosed in 200,000 men in the U.S. and 38,000 American males will die from this disease (Garnick, M.B. (1994). The Dilemmas of Prostate Cancer. Scientific American, April:72-81). Thus, prostate cancer is the
15 most frequently diagnosed malignancy (other than that of the skin) in U.S. men and the second leading cause of cancer-related deaths (behind lung cancer) in that group.

 Prostate specific Antigen (PSA) is a single chain 33 kDa glycoprotein that is produced almost exclusively by the human prostate
20 epithelium and occurs at levels of 0.5 to 2.0 mg/ml in human seminal fluid (Nadji, M., Taber, S.Z., Castro, A., et al. (1981) Cancer 48:1229; Papsidero, L., Kuriyama, M., Wang, M., et al. (1981). JNCI 66:37; Qui, S.D., Young, C.Y.F., Bihartz, D.L., et al. (1990), J. Urol. 144:1550; Wang, M.C., Valenzuela, L.A., Murphy, G.P., et al. (1979).
25 Invest. Urol. 17:159). The single carbohydrate unit is attached at asparagine residue number 45 and accounts for 2 to 3 kDa of the total molecular mass. PSA is a protease with chymotrypsin-like specificity (Christensson, A., Laurell, C.B., Lilja, H. (1990). Eur. J. Biochem. 194:755-763). It has been shown that PSA is mainly responsible for
30 dissolution of the gel structure formed at ejaculation by proteolysis of the major proteins in the sperm entrapping gel, Semenogelin I and Semenogelin II, and fibronectin (Lilja, H. (1985). J. Clin. Invest. 76:1899; Lilja, H., Oldbring, J., Rannevik, G., et al. (1987). J. Clin. Invest. 80:281; McGee, R.S., Herr, J.C. (1988). Biol. Reprod. 39:499).

- 2 -

The PSA mediated proteolysis of the gel-forming proteins generates several soluble Semenogelin I and Semenogelin II fragments and soluble fibronectin fragments with liquefaction of the ejaculate and release of progressively motile spermatozoa (Lilja, H., Laurell, C.B. (1984). Scand. J. Clin. Lab. Invest. 44:447; McGee, R.S., Herr, J.C. (1987). Biol. Reprod. 37:431). Furthermore, PSA may proteolytically degrade IGFBP-3 (insulin-like growth factor binding protein 3) allowing IGF to stimulate specifically the growth of PSA secreting cells (Cohen et al., (1992) J. Clin. Endo. & Meta. 75:1046-1053).

PSA complexed to alpha 1 - antichymotrypsin is the predominant molecular form of serum PSA and may account for up to 95% of the detected serum PSA (Christensson, A., Björk, T., Nilsson, O., et al. (1993). J. Urol. 150:100-105; Lilja, H., Christensson, A., Dahlén, U. (1991). Clin. Chem. 37:1618-1625; Stenman, U.H., Leinoven, J., Alfthan, H., et al. (1991). Cancer Res. 51:222-226). The prostatic tissue (normal, benign hyperplastic, or malignant tissue) is implicated to predominantly release the mature, enzymatically active form of PSA, as this form is required for complex formation with alpha 1 - antichymotrypsin (Mast, A.E., Enghild, J.J., Pizzo, S.V., et al. (1991). Biochemistry 30:1723-1730; Perlmutter, D.H., Glover, G.I., Rivetna, M., et al. (1990). Proc. Natl. Acad. Sci. USA 87:3753-3757). Therefore, in the microenvironment of prostatic PSA secreting cells the PSA is believed to be processed and secreted in its mature enzymatically active form not complexed to any inhibitory molecule. PSA also forms stable complexes with alpha 2 - macroglobulin, but as this results in encapsulation of PSA and complete loss of the PSA epitopes, the in vivo significance of this complex formation is unclear. A free, noncomplexed form of PSA constitutes a minor fraction of the serum PSA (Christensson, A., Björk, T., Nilsson, O., et al. (1993). J. Urol. 150:100-105; Lilja, H., Christensson, A., Dahlén, U. (1991). Clin. Chem. 37:1618-1625). The size of this form of serum PSA is similar to that of PSA in seminal fluid (Lilja, H., Christensson, A., Dahlén, U. (1991). Clin. Chem. 37:1618-1625) but it is yet unknown as to whether the free form of serum PSA may be a zymogen; an internally cleaved, inactive

- 3 -

form of mature PSA; or PSA manifesting enzyme activity. However, it seems unlikely that the free form of serum PSA manifests enzyme activity, since there is considerable (100 to 1000 fold) molar excess of both unreacted alpha 1 - antichymotrypsin and alpha 2 - macroglobulin in serum as compared with the detected serum levels of the free 33 kDa form of PSA (Christensson, A., Björk, T., Nilsson, O., et al. (1993). J. Urol. 150:100-105; Lilja, H., Christensson, A., Dahlén, U. (1991). Clin. Chem. 37:1618-1625).

Serum measurements of PSA are useful for monitoring the treatment of adenocarcinoma of the prostate (Duffy, M.S. (1989). Ann. Clin. Biochem. 26:379-387; Brawer, M.K. and Lange, P.H. (1989). Urol. Suppl. 5:11-16; Hara, M. and Kimura, H. (1989). J. Lab. Clin. Med. 113:541-548), although above normal serum concentrations of PSA have also been reported in benign prostatic hyperplasia and subsequent to surgical trauma of the prostate (Lilja, H., Christensson, A., Dahlén, U. (1991). Clin. Chem. 37:1618-1625). Prostate metastases are also known to secrete immunologically reactive PSA since serum PSA is detectable at high levels in prostatectomized patients showing widespread metastatic prostate cancer (Ford, T.F., Butcher, D.N., Masters, R.W., et al. (1985). Brit. J. Urology 57:50-55). Therefore, a cytotoxic compound that could be activated by the proteolytic activity of PSA should be prostate cell specific as well as specific for PSA secreting prostate metastases.

Accordingly, it is the object of this invention to provide novel oligopeptides which selectively are enzymatically cleaved by active free prostate specific antigen (PSA).

It is also the object of this invention to provide a quantitative assay for enzymatically active PSA which incorporates those novel oligopeptides.

It is further the object of this invention to provide a novel anti-cancer composition useful for the treatment of prostate cancer which comprises those novel oligopeptides in conjugation with a cytotoxic agent.

- 4 -

Another object of this invention is to provide a method of treating prostate cancer which comprises administration of novel anti-cancer composition.

5 SUMMARY OF THE INVENTION

The several points of cleavage where semenogelin I is selectively proteolytically cleaved by free PSA have been identified. Oligopeptides which comprise the amino acid sequences that are
10 recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Such oligopeptides are useful in assays which can determine the free PSA protease activity in vitro and in vivo. Furthermore, such oligopeptides may be incorporated into therapeutic agents which comprise conjugates of such oligopeptides and known
15 cytotoxic agents and which are useful in the treatment of prostatic cancer.

BRIEF DESCRIPTION OF THE FIGURES

20 FIGURES 1a and 1b: *Primary Amino Acid Sequence of Semenogelin I:* The primary amino acid sequence of Semenogelin I is shown. (SEQ.ID.NO.: 1) The PSA proteolytic cleavage sites ("CS") are shown (numbered in order of the relative affinity of a site towards PSA hydrolysis) and the protein fragments are numbered sequentially starting
25 at the amino terminus.

FIGURE 2: *Cleavage Affinity of Synthetic Oligopeptides:*
A nested set of synthetic oligopeptides was prepared and the oligopeptides were digested with enzymatically active free PSA for
30 various times. The results are shown in Table 2. ND = not determined. The single letter code for amino acids is used: A=Ala, E=Glu, G=Gly, H=His, I=Ile, K=Lys, L=Leu, N=Asn, Q=Gln, R=Arg, S=Ser, T=Thr, Y=Tyr.

FIGURES 3a and 3b: *Cleavage Affinity of Synthetic Oligopeptides:*

- 5 -

Synthetic oligopeptides were prepared and the oligopeptides were digested with enzymatically active free PSA for four (4) hours. The percentage of the oligopeptide that is cleaved in this period of time is listed. The results are shown in Table 4.

5

FIGURE 4: Cytotoxicity Data of Non-cleavable Oligopeptide-Doxorubicin Conjugates:

The data of the figure shows comparative cytotoxicity of doxorubicin and a conjugate of doxorubicin covalently bound to an oligopeptide (Compound 12d) that does not contain the free PSA proteolytic cleavage site. The IC₅₀ for doxorubicin is 0.3 μ M, while the acetylated oligopeptide modified doxorubicin has an IC₅₀ that has been reduced by greater than 300 fold. This conjugate had no HPLC detectable contamination with unmodified doxorubicin. The oligopeptide alone had no detectable cell killing activity.

10

15

FIGURE 5: Cleavage Affinity of Oligopeptides in Conjugation with Doxorubicin by Free PSA In Vitro:

Oligopeptides-doxorubicin conjugates were prepared and the conjugates were digested with enzymatically active free PSA for four (4) hours. The percentage conjugate that is enzymatically cleaved in the oligopeptide in this period of time is listed. The results are shown in Table 5.

20

25

FIGURE 6: Cleavage Affinity of Oligopeptides in Conjugation with Doxorubicin in Cell Conditioned Media:

Oligopeptides-doxorubicin conjugates were reacted for four (4) hours with cell culture media that had been conditioned by exposure to LNCaP cells (which are known to secrete free PSA) or DuPRO cell (which do not secrete free PSA). The percentage conjugate that is enzymatically cleaved in the oligopeptide in this period of time is listed. The results are shown in Table 6.

30

FIGURE 7: Cytotoxicity Data of Cleavable Oligopeptide-Doxorubicin Conjugates:

- 6 -

The data in Table 7 shows cytotoxicity (as IC₅₀) of conjugates of doxorubicin covalently bound to an oligopeptide that contain a free PSA proteolytic cleavage site against a cancer cell line that is known to secrete free PSA. Also shown for selected conjugates is the cytotoxicity of the conjugate against a cell line (DuPRO) which does not secrete free PSA.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to novel oligopeptides which are specifically recognized by the free prostate specific antigen (PSA) and are capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen. Such oligopeptides include oligomers that comprise an amino acid sequence selected from:

- a) AsnLysIleSerTyrGln|Ser (SEQ.ID.NO.: 13),
- b) LysIleSerTyrGln|Ser (SEQ.ID.NO.: 14),
- c) GlyGluAsnGlyValGlnLysAspValSerGlnXaaSerIleTyr|SerGlnThrGlu (SEQ.ID.NO.: 15),
- d) GlyLysGlyIleSerSerGlnTyr|SerAsnThrGluGluArgLeu (SEQ.ID.NO.: 2),
- e) AsnLysIleSerTyrTyr|Ser (SEQ.ID.NO.: 127),
- f) AsnLysAlaSerTyrGln|Ser (SEQ.ID.NO.: 128),
- g) SerTyrGln|SerSer (SEQ.ID.NO.: 129);
- h) LysTyrGln|SerSer (SEQ.ID.NO.: 140); and
- i) hArgTyrGln|SerSer (SEQ.ID.NO.: 141);

wherein hArg is homoarginine and Xaa is any natural amino acid.

- 7 -

In an embodiment of the instant invention, the oligopeptides include oligomers that comprise an amino acid sequence that is selected from:

- 5 a) AsnLysIleSerTyrGlnI SerSer (SEQ.ID.NO.: 16),
b) AsnLysIleSerTyrGlnI SerAla (SEQ.ID.NO.: 130),
10 c) AsnLysIleSerTyrGlnI SerSerSer (SEQ.ID.NO.: 17),
d) AlaAsnLysIleSerTyrGlnI SerSerSer (SEQ.ID.NO.: 18),
e) LysIleSerTyrGlnI SerSerSerThrGlu (SEQ.ID.NO.: 19),
15 f) GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyrI SerGlnThrGlu
(SEQ.ID.NO.: 4),
g) GlyGluAsnGlyValGlnLysAspValSerGlnSerSerIleTyrI SerGlnThrGlu
20 (SEQ.ID.NO.: 5),
h) AlaAsnLysIleSerTyrTyrI Ser (SEQ.ID.NO.: 131),
i) AlaAsnLysAlaSerTyrGlnI Ser (SEQ.ID.NO.: 132),
25 j) SerTyrGlnI SerSerThr (SEQ.ID.NO.: 133),
k) SerTyrGlnI SerSerSer (SEQ.ID.NO.: 134),
30 l) LysTyrGlnI SerSerSer (SEQ.ID.NO.: 142),
m) hArgTyrGlnI SerSerSer (SEQ.ID.NO.: 143), and
n) SerTyrGlnI SerSerLeu (SEQ.ID.NO.: 135).

- 8 -

In a more preferred embodiment of the instant invention, the oligopeptides include oligomers that comprise an amino acid sequence that is selected from:

5

a) AsnLysIleSerTyrGlnIleSerSerSerThr (SEQ.ID.NO.: 10),

b) AlaAsnLysIleSerTyrGlnIleSerAla (SEQ.ID.NO.: 136),

10

c) AsnLysIleSerTyrGlnIleSerSerSerThrGlu (SEQ.ID.NO.: 3),

d) AlaAsnLysIleSerTyrGlnIleSerSerSerThrGlu (SEQ.ID.NO.: 11),

15

e) GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyrIleSerGlnThrGlu (SEQ.ID.NO.: 4),

f) AlaAsnLysIleSerTyrTyrIleSerSer (SEQ.ID.NO.: 137),

20

g) AlaAsnLysIleSerTyrTyrIleSerAla (SEQ.ID.NO.: 138),

h) AlaAsnLysAlaSerTyrGlnIleSerAla (SEQ.ID.NO.: 139),

i) AlaSerTyrGlnIleSerSerLeu (SEQ.ID.NO.: 94).

25

In a further embodiment of the instant invention, the oligopeptides include oligomers that comprise an amino acid sequence that is selected from:

30

a) GlyArgLysAlaAsnLysIleSerTyrGlnIleSerSerSerThrGluGluArgArgLeuHisTyr GlyGluAsnGly (SEQ.ID.NO.: 6).

The phrase "oligomers that comprise an amino acid sequence" as used hereinabove, and elsewhere in the Detailed Description of the Invention, describes oligomers of from about 6 to

- 9 -

about 100 amino acids residues which include in their amino acid sequence the specific amino acid sequence described and which are therefore proteolytically cleaved within the amino acid sequence described by free PSA. Thus, for example, the following oligomer:

5 GlnLeuAspAsnLysIleSerTyrGlnI SerSerSerThrHisGlnSerSer
(SEQ.ID.NO.: 20)

comprises the amino acid sequence:

AsnLysIleSerTyrGlnI SerSerSerThr (SEQ.ID.NO.:10) and would
10 therefore come within the instant invention. It is understood that such
oligomers do not include semenogelin I and semenogelin II.

It is also understood that the instant invention includes oligomers wherein the N-terminus amino acid or the C-terminus amino acid, or both terminus amino acids are modified. Such modifications include, but are not limited to, acylation of the amine group at the N-terminus and formation of an amide to replace the carboxylic acid at the
15 C-terminus. Addition of such moieties may be performed during solid-phase synthesis of the oligomer; thus, attachment of the C-terminus amino acid to a solid phase resin may be through an amine which results in an amide moiety upon acidic cleavage of the oligomer from the resin.
20 Thus the following compounds are considered "oligomers that comprise an amino acid sequence" as used hereinabove and are meant to be illustrative and are not limiting:

25 AlaAsnLysIleSerTyrGlnI SerSerSerThrGlu-amide (SEQ.ID.NO.: 11)
Ac-AlaAsnLysIleSerTyrGlnI SerSerSerThrLeu (SEQ.ID.NO.: 70)

Ac-AlaAsnLysIleSerTyrGlnI SerSerSerThrGlu-amide (SEQ.ID.NO.: 11)
Ac-AlaAsnLysIleSerTyrGlnI SerSerSerThrLeu-amide (SEQ.ID.NO.: 70)
30 Ac-AlaAsnLysIleSerTyrGlnI SerAlaSerThrGlu-amide (SEQ.ID.NO.: 73)
Ac-AlaAsnLysIleSerTyrGlnI SerSerLysThrGlu-amide (SEQ.ID.NO.: 74)
Ac-AlaAsnLysIleSerTyrGlnI SerSerThrGlu-amide (SEQ.ID.NO.: 75)
Ac-AlaAsnLysIleSerTyrGlnI SerSerGlnThrGlu-amide (SEQ.ID.NO.: 78)
Ac-AlaAsnLysIleSerTyrGlnI SerAlaLysThrGlu-amide (SEQ.ID.NO.:79)
Ac-AlaAsnLysIleSerTyrGlnI SerThrGlu-amide (SEQ.ID.NO.: 81)

- 10 -

- Ac-AlaAsnLysSerTyrGlnlSerSerThrGlu-amide (SEQ.ID.NO.: 82)
 Ac-AlaAsnLysAlaSerTyrGlnlSerAlaSerThrGlu-amide (SEQ.ID.NO.: 84)
 5 Ac-AlaAsnGluIleSerTyrGlnlSerAlaSerThrGlu-amide (SEQ.ID.NO.: 85)
 Ac-AsnLysIleSerTyrGlnlSerSer-amide (SEQ.ID.NO.: 16)
 Ac-LysIleSerTyrGlnlSerSer-amide (SEQ.ID.NO.: 86)
 Ac-SerTyrGlnlSerSerThrGlu-amide (SEQ.ID.NO.: 87)
 Ac-AlaSerTyrGlnlSerSerThrGlu-amide (SEQ.ID.NO.: 89)
 Ac-AlaAsnLysIleSerTyrTyrIleSerSerSerThrGlu-amide (SEQ.ID.NO.: 92)
 10 Ac-AlaAsnLysIleSerTyrTyrIleSerAlaSerThrGlu-amide (SEQ.ID.NO.: 93)
 Ac-AlaSerTyrGlnlSerSerLeu-amide (SEQ.ID.NO.: 94)
 Ac-AlaAsnSerTyrGlnlSerSerSerThrGlu-amide (SEQ.ID.NO.: 95)
 Ac-AlaSerTyrGlnlSerSerSerThrGlu-amide (SEQ.ID.NO.: 96)
 Ac-SerTyrGlnlSerSerSerThrGlu-amide (SEQ.ID.NO.: 97)
 15 Ac-AlaAsnLysAlaSerTyrGlnlSerAlaSerCys-amide (SEQ.ID.NO.: 98)

A person of ordinary skill in the peptide chemistry art would readily appreciate that certain amino acids in a biologically active oligopeptide may be replaced by other homologous, isosteric and/or
 20 isoelectronic amino acids wherein the biological activity of the original oligopeptide has been conserved in the modified oligopeptide. The following list of amino acid replacements is meant to be illustrative and is not limiting:

25	<u>Original Amino Acid</u>	<u>Replacement Amino Acid(s)</u>
	Ala	Gly
	Arg	Lys, Ornithine
	Asn	Gln
	Asp	Glu
30	Glu	Asp
	Gln	Asn
	Gly	Ala
	Ile	Val, Leu, Met, Nle
	Leu	Ile, Val, Met, Nle

- 11 -

	Lys	Arg, Ornithine
	Met	Leu, Ile, Nle, Val
	Ornithine	Lys, Arg
5	Phe	Tyr, Trp
	Ser	Thr
	Thr	Ser
	Trp	Phe, Tyr
	Tyr	Phe, Trp
10	Val	Leu, Ile, Met, Nle

Thus, for example, the following oligopeptides may be synthesized by techniques well known to persons of ordinary skill in the art and would be expected to be proteolytically cleaved by free PSA:

15	AsnArgIleSerTyrGlnSer	(SEQ.ID.NO.: 21)
	AsnLysValSerTyrGlnSer	(SEQ.ID.NO.: 22)
	AsnLysMetSerTyrGlnSerSer	(SEQ.ID.NO.: 23)
	AsnLysLeuSerTyrGlnSerSer	(SEQ.ID.NO.: 24)
20	AsnLysIleThrTyrGlnSerSerSer	(SEQ.ID.NO.: 25)
	AsnLysIleSerPheGlnSerSerSer	(SEQ.ID.NO.: 26)
	AsnLysIleSerTrpGlnSerSerSerThr	(SEQ.ID.NO.: 27)
	AsnLysIleSerTyrAsnSerSerSerThr	(SEQ.ID.NO.: 28)
	AsnLysIleSerTyrGlnThrSerSerThr	(SEQ.ID.NO.: 29)
25	AsnLysIleSerTyrGlnSer	(SEQ.ID.NO.: 30)
	GlnLysIleSerTyrGlnSerSer	(SEQ.ID.NO.: 31)
	AsnArgIleThrTyrGlnSerSerSer	(SEQ.ID.NO.: 32)
	AsnArgIleSerPheGlnSerSerSerThr	(SEQ.ID.NO.: 33)
	AsnArgIleSerTrpGlnSerSerSerThr	(SEQ.ID.NO.: 35)
30	AsnArgIleSerTyrGlnThrSerSerThr	(SEQ.ID.NO.: 36)
	AsnLysIleThrTyrGlnThrSerSerThr	(SEQ.ID.NO.: 37)
	AsnLysLeuSerTyrGlnThrSerSerThr	(SEQ.ID.NO.: 38)
	GlnLysLeuSerTyrGlnSerSerSerThr	(SEQ.ID.NO.: 39)
	AsnArgLeuSerTyrGlnThrSerSerThr	(SEQ.ID.NO.: 40)
	AsnLysValSerPheGlnSerSerSerThr	(SEQ.ID.NO.: 41)

- 12 -

AsnArgValSerTrpGlnSerSerSerThr (SEQ.ID.NO.: 42)
GlnLysValSerTyrGlnSerSerSerThr (SEQ.ID.NO.: 43)
GlnLysIleSerTyrGlnThrSerSerThr (SEQ.ID.NO.: 34)
AsnLysIleSerTyrGlnSerSerSerThr (SEQ.ID.NO.: 44)

5

Similarly, the following oligopeptides may be synthesized by techniques well known to persons of ordinary skill in the art and would be expected to be proteolytically cleaved by free PSA:

10 GlyGluGlnGlyValGlnLysAspValSerGlnSerSerIleTyrSerGlnThrGlu
(SEQ.ID.NO.: 45),
GlyGluAsnGlyLeuGlnLysAspValSerGlnSerSerIleTyrSerGlnThrGlu
(SEQ.ID.NO.: 47),
15 GlyGluAsnGlyValAsnLysAspValSerGlnSerSerIleTyrSerGlnThrGlu
(SEQ.ID.NO.: 48),
GlyGluAsnGlyValGlnArgAspValSerGlnArgSerIleTyrSerGlnThrGlu
(SEQ.ID.NO.: 49),
GlyGluAsnGlyValGlnLysAspValSerGlnLysSerIleTyrSerGlnThrGlu
(SEQ.ID.NO.: 50),
20 GlyGluAsnGlyValGlnLysAspLeuSerGlnThrSerIleTyrSerGlnThrGlu
(SEQ.ID.NO.: 51),
GlyGluAsnGlyValGlnLysAspValSerGlnSerSerIlePheSerGlnThrGlu
(SEQ.ID.NO.: 52),
25 GlyGluAsnGlyValGlnLysAspMetSerGlnSerSerIleTyrThrGlnThrGlu
(SEQ.ID.NO.: 53),
GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyrThrGlnThrGlu
(SEQ.ID.NO.: 54),
GlyGluAsnGlyValGlnLysAspValSerGlnSerSerIleTyrSerGlnSerGlu
(SEQ.ID.NO.: 55),
30 GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyrSerAsnThrGlu
(SEQ.ID.NO.: 56),
GlyLysAlaIleSerSerGlnTyrSerAsnThrGluGluArgLeu (SEQ.ID.NO.:
57),

- 13 -

- GlyArgGlyIleSerSerGlnTyrI SerAsnThrGluGluArgLeu (SEQ.ID.NO.: 59),
GlyLysGlyIleThrSerGlnTyrI SerAsnThrGluGluArgLeu (SEQ.ID.NO.: 60),
5 GlyLysGlyIleSerThrGlnTyrI SerAsnThrGluGluArgLeu (SEQ.ID.NO.: 61),
GlyLysGlyIleSerSerAsnTyrI SerAsnThrGluGluArgLeu (SEQ.ID.NO.: 62),
10 AlaLysGlyIleSerSerGlnTyrI SerAsnThrGluGluArgLeu (SEQ.ID.NO.: 63),
GlyLysGlyIleSerSerGlnPheI SerAsnThrGluGluArgLeu (SEQ.ID.NO.: 64),
GlyLysGlyIleSerSerGlnTyrI ThrAsnThrGluGluArgLeu (SEQ.ID.NO.: 65),
15 GlyLysGlyIleSerSerGlnTyrI SerAsnSerGluGluArgLeu (SEQ.ID.NO.: 58), and
GlyLysGlyIleSerSerGlnTyrI SerAsnThrAspGluArgLeu (SEQ.ID.NO.: 46);
20 and the like.

The inclusion of the symbol "I" within an amino acid sequence indicates the point within that sequence where the oligopeptide is proteolytically cleaved by free PSA.

The invention also concerns a method for assaying proteolytic free PSA activity in a composition. This is an important
25 aspect of the invention in that such an assay system provides one with the ability to measure quantitatively the amount of free PSA present in certain physiological fluids and tissues. Such an assay will also provide not only the ability to follow isolation and purification of free PSA, but
30 also is a basis for a screening assay for inhibitors of the proteolytic activity of free PSA. The assay method generally includes simply determining the ability of a composition suspected of containing enzymatically active free PSA to proteolytically cleave the oligopeptide.

Typically, the assay protocol is carried out using one of the oligopeptides described hereinabove. However, one may find a particular

- 14 -

benefit in construction of an assay wherein the oligopeptide containing the cleavage site is labeled so that one can measure the appearance of such a label, for example, a radioactive label, in both the uncleaved oligopeptide and the portion of the oligopeptide remaining after cleavage which contains the label.

The instant invention further relates to a method for identifying compounds (hereinafter referred to as candidate compounds) that will inhibit the proteolytic activity of free PSA. It is contemplated that this screening technique will prove useful in the general identification of any candidate compound that will serve such as an inhibitory purpose, whether or not the candidate compound is proteinaceous or peptidyl in structure.

Thus, the present invention is also directed to a method for determining the ability of a test substance to inhibit the proteolytic activity of free PSA, the method which comprises:

- (a) reacting a substrate, wherein the substrate comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen, with free prostate specific antigen in the presence of a test substance; and
- (b) detecting whether the substrate has been cleaved, in which the ability of the test substance to inhibit proteolytic activity of prostate specific antigen is indicated by a decrease in the cleavage of the substrate as compared to the cleavage of the substrate in the absence of the test substance.

The candidate screening assay is quite simple to set up and perform, and is related in many ways to the assay discussed above for determining proteolytic activity. Thus, after obtaining a relatively purified preparation of free PSA, one will desire to simply admix a test substance with the proteolytic preparation, preferably under conditions which would allow the PSA to perform its cleavage function but for

- 15 -

inclusion of an inhibitory substance. Thus, for example, one will typically desire to include within the admixture an amount of a known oligopeptide having a PSA specific cleavage site, such as those oligopeptides described hereinabove. In this fashion, one can measure the ability of the test substance to reduce cleavage of the oligopeptide relatively in the presence of the test substance.

Accordingly, one will desire to measure or otherwise determine the activity of the free PSA in the absence of the added test substance relative to the activity in the presence of the test substance in order to assess the relative inhibitory capability of the test substance.

The instant invention also relates to novel anti-cancer compositions useful for the treatment of prostate cancer. Such compositions comprise the oligopeptides of the instant invention covalently bonded directly, or through a chemical linker, to a cytotoxic agent. Such a combination of an oligopeptide and cytotoxic agent may be termed a conjugate. Ideally, the cytotoxic activity of the cytotoxic agent is greatly reduced or absent when the oligopeptide containing the PSA proteolytic cleavage site is bonded directly, or through a chemical linker, to the cytotoxic agent and is intact. Also ideally, the cytotoxic activity of the cytotoxic agent increases significantly or returns to the activity of the unmodified cytotoxic agent upon proteolytic cleavage of the attached oligopeptide at the cleavage site. While it is not necessary for practicing this aspect of the invention, the most preferred embodiment of this aspect of the invention is a conjugate wherein the oligopeptide, and the chemical linker if present, are detached from the cytotoxic agent by the proteolytic activity of the free PSA and any other native proteolytic enzymes present in the tissue proximity, thereby releasing unmodified cytotoxic agent into the physiological environment at the place of proteolytic cleavage.

It is understood that the oligopeptide of the instant invention that is conjugated to the cytotoxic agent, whether through a direct covalent bond or through a chemical linker, does not need to be the oligopeptide that has the greatest recognition by free PSA and is most readily proteolytically cleaved by free PSA. Thus, the oligopeptide that

- 16 -

is selected for incorporation in such an anti-cancer composition will be chosen both for its selective, proteolytic cleavage by free PSA and for the cytotoxic activity of the cytotoxic agent-proteolytic residue conjugate (or, in what is felt to be an ideal situation, the unmodified cytotoxic agent) which results from such a cleavage.

Because the conjugates of the invention can be used for modifying a given biological response, cytotoxic agent is not to be construed as limited to classical chemical therapeutic agents. For example, the cytotoxic agent may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, α -interferon, β -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.


The preferred cytotoxic agents include, in general, alkylating agents, antiproliferative agents, tubulin binding agents and the like. Preferred classes of cytotoxic agents include, for example, the anthracycline family of drugs, the vinca drugs, the mitomycins, the bleomycins, the cytotoxic nucleosides, the pteridine family of drugs, diynenes, and the podophyllotoxins. Particularly useful members of those classes include, for example, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, podophyllotoxin, or podophyllotoxin derivatives such as etoposide or etoposide phosphate, melphalan, vinblastine, vincristine, leurosine, vindesine, leurosine and the like. Other useful cytotoxic agents include estramustine, cisplatin and cyclophosphamide. One skilled in the art may make chemical modifications to the desired compound in order to make reactions of that

- 17 -

compound more convenient for purposes of preparing conjugates of the invention.

A highly preferred group of cytotoxic agents for the present invention include drugs of the following formulae:

THE METHOTREXATE GROUP OF FORMULA (1):




(1)

in which

- R¹² is amino or hydroxy;
 R⁷ is hydrogen or methyl;
 R⁸ is hydrogen, fluoro, chloro, bromo or iodo;
 R⁹ is hydroxy or a moiety which completes a salt of the carboxylic acid;

THE MITOMYCIN GROUP OF FORMULA (2):




(2)


in which

- R¹⁰ is hydrogen or methyl;


- 18 -

THE BLEOMYCIN GROUP OF FORMULA (3)


in which R¹¹ is hydroxy, amino, C₁-C₃ alkylamino, di(C₁-C₃ alkyl)amino, C₄-C₆ polymethylene amino,



- 19 -

MELPHALAN OF FORMULA (4):6-MERCAPTOPURINE OF FORMULA (5):

10




15

(5)

A CYTOSINE ARABINOSIDE OF FORMULA (6):

20




25

(6)

30

THE PODOPHYLLOTOXINS OF FORMULA(7):




15 in which

R¹³ is hydrogen or methyl;

R¹⁴ is methyl or thienyl;


or a phosphate salt thereof;

20 THE VINCA ALKALOID GROUP OF DRUGS OF FORMULA (8):








- 21 -

in which

R¹⁵ is H, CH₃ or CHO; when R¹⁷ and R¹⁸ are taken singly;R¹⁸ is H, and one of R¹⁶ and R¹⁷ is ethyl and the other is H or OH; when R¹⁷ and R¹⁸ are taken together with thecarbons to which they are attached, they form an oxirane ring in which case R¹⁶ is ethyl;R¹⁹ is hydrogen, (C₁-C₃ alkyl)-CO, or chlorosubstituted (C₁-C₃ alkyl)-CO;DIFLUORONUCLEOSIDES OF FORMULA (9):

(9)

in which

R²¹ is a base of one of the formulae:

in which

R²² is hydrogen, methyl, bromo, fluoro, chloro or iodo;

- 22 -

R²³ is -OH or -NH₂;


R²⁴ is hydrogen, bromo, chloro or iodo;
or,

5

THE ANTHRACYCLINES ANTIBIOTICS OF FORMULA (10):

10

15



(10)

20

wherein

R¹ is -CH₃, -CH₂OH, -CH₂OCO(CH₂)₃CH₃, or
-CH₂OCOCH(OC₂H₅)₂;

R³ is -OCH₃, -OH or -H;

25



R⁴ is -NH₂, -NHCOCF₃, 4-morpholinyl, 3-cyano-4-
morpholinyl, 1-piperidinyl, 4-methoxy-1-piperidinyl,
benzylamine, dibenzylamine, cyanomethylamine, or 1-
cyano-2-methoxyethyl amine;

R⁵ is -OH -OTHP or -H; and

30

R⁶ is -OH or -H provided that
R⁶ is not -OH when R⁵ is -OH or -OTHP.

- 23 -

ESTRAMUSTINE (11)CYCLOPHOSPHAMIDE (12)

The most highly preferred drugs are the anthracycline
20 antibiotic agents of Formula (10), described previously. One skilled in
the art understands that this structural formula includes compounds which
are drugs, or are derivatives of drugs, which have acquired in the art
different generic or trivial names. Table 1, which follows, represents a
number of anthracycline drugs and their generic or trivial names and
25 which are especially preferred for use in the present invention.

30

- 24 -

5


10

15
Table I

20

25

30



Compound	R ₁	R ₃	R ₄	R ₅	R ₆
daunorubicin ^a	CH ₃	OCH ₃	NH ₂	OH	H
doxorubicin ^b	CH ₂ OH	OCH ₃	NH ₂	OH	H
detorubicin	CH ₂ OCOCH(OC ₂ H ₅) ₂	OCH ₃	NH ₂	OH	H
carminomycin	CH ₃	OH	NH ₂	OH	H
idarubicin	CH ₃	H	NH ₂	OH	H
epirubicin	CH ₂ OH	OCH ₃	NH ₂	OH	OH
esorubicin	CH ₂ OH	OCH ₃	NH ₂	H	H
THP	CH ₂ OH	OCH ₃	NH ₂	OTHP	H
AD-32	CH ₂ OCO(CH ₂) ₃ CH ₃	OCH ₃	NHCOCF ₃	OH	H

^a"daunomycin" is an alternative name for daunorubicin

^b"adriamycin" is an alternative name for doxorubicin

- 25 -

Of the compounds shown in Table 1, the most highly preferred drug is doxorubicin. Doxorubicin (also referred to herein as "DOX") is that anthracycline of Formula (10) in which R₁ is -CH₂OH, R₃ is -OCH₃, R₄ is -NH₂, R₅ is -OH, and R₆ is -H.

5

The oligopeptides, peptide subunits and peptide derivatives (also termed "peptides") of the present invention can be synthesized from their constituent amino acids by conventional peptide synthesis techniques, preferably by solid-phase technology. The peptides are then purified by reverse-phase high performance liquid chromatography (HPLC).

10

Standard methods of peptide synthesis are disclosed, for example, in the following works: Schroeder *et al.*, "The Peptides", Vol. I, Academic Press 1965; Bodansky *et al.*, "Peptide Synthesis", Interscience Publishers, 1966; McOmie (ed.) "Protective Groups in Organic Chemistry", Plenum Press, 1973; Barany *et al.*, "The Peptides: Analysis, Synthesis, Biology" 2, Chapter 1, Academic Press, 1980, and Stewart *et al.*, "Solid Phase Peptide Synthesis", Second Edition, Pierce Chemical Company, 1984. The teachings of these works are hereby incorporated by reference.

15

20

The conjugates of the instant invention which comprise the oligopeptide containing the PSA cleavage site and a cytotoxic agent may similarly be synthesized by techniques well known in the medicinal chemistry art. For example, a free amine moiety on the cytotoxic agent may be covalently attached to the oligopeptide at the carboxyl terminus such that an amide bond is formed. Similarly, an amide bond may be formed by covalently coupling an amine moiety of the oligopeptide and a carboxyl moiety of the cytotoxic agent. For these purposes a reagent such as a combination of 2-(1H-benzotriazol-1-yl)-1,3,3-tetramethyluronium hexafluorophosphate (known as HBTU) and 1-hydroxybenzotriazole hydrate (known as HOBT), dicyclohexylcarbodiimide (DCC), N-ethyl-N-(3-dimethylaminopropyl)-carbodiimide (EDC), diphenylphosphorylazide (DPPA), benzotriazol-1-yl-oxy-tris-

25

30

- 26 -

(dimethylamino)phosphonium hexafluorophosphate (BOP) and the like may be utilized.

Furthermore, the instant conjugate may be formed by a non-peptidyl bond between the PSA cleavage site and a cytotoxic agent. For example, the cytotoxic agent may be covalently attached to the carboxyl terminus of the oligopeptide via a hydroxyl moiety on the cytotoxic agent, thereby forming an ester linkage. For this purpose a reagent such as a combination of HBTU and HOBT, a combination of BOP and imidazole, a combination of DCC and DMAP, and the like may be utilized. The carboxylic acid may also be activated by forming the nitrophenyl ester or the like and reacted in the presence of DBU (1,8-diazabicyclo[5,4,0]undec-7-ene).

The instant conjugate may also be formed by attachment of the oligopeptide to the cytotoxic agent via a linker unit. Such linker units include, for example, a biscarbonyl alkyl diradical whereby an amine moiety on the cytotoxic agent is connected with the linker unit to form an amide bond and the amino terminus of the oligopeptide is connected with the other end of the linker unit also forming an amide bond. Other such linker units which are stable to the physiological environment when not in the presence of free PSA, but are cleavable upon the cleavage of the PSA proteolytic cleavage site, are also envisioned. Furthermore, linker units may be utilized that, upon cleavage of the PSA proteolytic cleavage site, remain attached to the cytotoxic agent but do not significantly decrease the cytotoxic activity of such a post-cleavage cytotoxic agent derivative when compared with an unmodified cytotoxic agent.

One skilled in the art understands that in the synthesis of compounds of the invention, one may need to protect or block various reactive functionalities on the starting compounds and intermediates while a desired reaction is carried out on other portions of the molecule. After the desired reactions are complete, or at any desired time, normally such protecting groups will be removed by, for example, hydrolytic or hydrogenolytic means. Such protection and deprotection steps are conventional in organic chemistry. One skilled in the art is referred to Protective Groups in Organic Chemistry, McOmie, ed., Plenum Press,

- 27 -

NY, NY (1973); and, Protective Groups in Organic Synthesis, Greene, ed., John Wiley & Sons, NY, NY (1981) for the teaching of protective groups which may be useful in the preparation of compounds of the present invention.

5 By way of example only, useful amino-protecting groups may include, for example, C₁-C₁₀ alkanoyl groups such as formyl, acetyl, dichloroacetyl, propionyl, hexanoyl, 3,3-diethylhexanoyl, γ -chlorobutyl, and the like; C₁-C₁₀ alkoxycarbonyl and C₅-C₁₅
10 aryloxycarbonyl groups such as tert-butoxycarbonyl, benzyloxycarbonyl, allyloxycarbonyl, 4-nitrobenzyloxycarbonyl, fluorenylmethyloxycarbonyl and cinnamoyloxycarbonyl; halo-(C₁-C₁₀)-alkoxycarbonyl such as 2,2,2-trichloroethoxycarbonyl; and C₁-C₁₅ arylalkyl and alkenyl group such as benzyl, phenethyl, allyl, trityl, and the like. Other commonly
15 used amino-protecting groups are those in the form of enamines prepared with β -keto-esters such as methyl or ethyl acetoacetate.


Useful carboxy-protecting groups may include, for example, C₁-C₁₀ alkyl groups such as methyl, tert-butyl, decyl; halo-C₁-C₁₀ alkyl such as 2,2,2-trichloroethyl, and 2-iodoethyl; C₅-C₁₅ arylalkyl such as
20 benzyl, 4-methoxybenzyl, 4-nitrobenzyl, triphenylmethyl, diphenylmethyl; C₁-C₁₀ alkanoyloxymethyl such as acetoxymethyl, propionoxymethyl and the like; and groups such as phenacyl, 4-halophenacyl, allyl, dimethylallyl, tri-(C₁-C₃ alkyl)silyl, such as trimethylsilyl, β -p-toluenesulfonylethyl, β -p-nitrophenyl-thioethyl, 2,4,6-
25 trimethylbenzyl, β -methylthioethyl, phthalimidomethyl, 2,4-dinitrophenylsulphenyl, 2-nitrobenzhydryl and related groups.

Similarly, useful hydroxy protecting groups may include, for example, the formyl group, the chloroacetyl group, the benzyl group, the benzhydryl group, the trityl group, the 4-nitrobenzyl group, the
30 trimethylsilyl group, the phenacyl group, the tert-butyl group, the methoxymethyl group, the tetrahydropyranyl group, and the like.

With respect to the preferred embodiment of an oligopeptide combined with the anthracycline antibiotic doxorubicin, the following Reaction Schemes illustrate the synthesis of the conjugates of the instant invention.


- 28 -

REACTION SCHEME I




- 29 -

REACTION SCHEME II




- 30 -

REACTION SCHEME III




- 31 -

REACTION SCHEME IV



- 32 -

REACTION SCHEME V




- 33 -

Reaction Scheme VI illustrates preparation of conjugates of the oligopeptides of the instant invention and the vinca alkaloid cytotoxic agent vinblastine. Attachement of the N-terminus of the oligopeptide to vinblastine is illustrated (S.P. Kandukuri et al. J. Med. Chem. 28:1079-1088 (1985)). However, conjugation of the oligopeptide at other positions and functional groups of vinblastine and at the C-terminus of the oligopeptide is also expected to provide compounds useful in the treatment of prostate cancer.

It is also understood that conjugates may be prepared wherein the N-terminus of the oligopeptide of the instant invention is covalently attached to one cytotoxic agent, such as vinblastine, while the C-terminus is simultaneously attached to another cytotoxic agent, which is the same or different cytotoxic agent, such as doxorubicin. Such a polycytotoxic conjugate may offer advantages over a conjugate containing only one cytotoxic agent.


- 34 -

REACTION SCHEME VI



- 35 -

REACTION SCHEME VI




- 36 -

The oligopeptide-cytotoxic agent conjugate of the instant invention wherein the cytotoxic agent is the preferred cytotoxic agent doxorubicin may be described by the general formula I below:

5

10

15



wherein:

20 oligopeptide is an oligopeptide which is specifically recognized by the free prostate specific antigen (PSA) and is capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen;

25 X_L is absent or is an amino acid selected from:

- a) phenylalanine,
- b) leucine,
- c) valine,
- d) isoleucine,
- 30 e) (2-naphthyl)alanine,
- f) cyclohexylalanine,
- g) diphenylalanine,
- h) norvaline, and
- j) norleucine;

- 37 -

R is hydrogen or $-(C=O)R^1$; and

R^1 is C₁-C₆-alkyl or aryl.

5 In a preferred embodiment of the oligopeptide-cytotoxic agent conjugate:

oligopeptide is an oligomer that comprises an amino acid sequence selected from:

- 10 a) AsnLysIleSerTyrGlnSer (SEQ.ID.NO.: 13),
- b) LysIleSerTyrGlnSer (SEQ.ID.NO.: 14),
- 15 c) GlyGluAsnGlyValGlnLysAspValSerGlnXaaSerIleTyrIleSerGlnThrGlu (SEQ.ID.NO.: 15),
- d) GlyLysGlyIleSerSerGlnTyrIleSerAsnThrGluGluArgLeu (SEQ.ID.NO.: 2),
- 20 e) AsnLysIleSerTyrTyrIleSer (SEQ.ID.NO.: 127),
- f) AsnLysAlaSerTyrGlnSer (SEQ.ID.NO.: 128),
- 25 g) SerTyrGlnIleSerSer (SEQ.ID.NO.: 129), and
- h) hArgTyrGlnIleSerSer (SEQ.ID.NO.: 141);

30 wherein Xaa is any natural amino acid;

X_L is absent or is an amino acid selected from:

- a) leucine,
b) isoleucine,
c) norleucine, and

- 38 -

d) valine; and

R is acetyl, pivaloyl or benzoyl.


5

The following compounds are specific examples of the oligopeptide-cytotoxic agent conjugate of the instant invention:

10

15


20




wherein X is:

25

30



- 39 -



25 It is well known in the art, and understood in the instant invention, that peptidyl therapeutic agents such as the instant oligopeptide-cytotoxic agent conjugates preferably have the terminal amino moiety of any oligopeptide substituent protected with a suitable protecting group, such as acetyl, benzoyl, pivaloyl and the like. Such
 30 protection of the terminal amino group reduces or eliminates the enzymatic degradation of such peptidyl therapeutic agents by the action of exogenous amino peptidases which are present in the blood plasma of warm blooded animals.

The oligopeptide-cytotoxic agent conjugates of the invention are administered to the patient in the form of a pharmaceutical

- 40 -

composition which comprises a conjugate of Formula (I) and a pharmaceutically acceptable carrier, excipient or diluent therefor. As used, "pharmaceutically acceptable" refers to those agents which are useful in the treatment or diagnosis of a warm-blooded animal including, for example, a human, equine, porcine, bovine, murine, canine, feline, or other mammal, as well as an avian or other warm-blooded animal. The preferred mode of administration is parenterally, particularly by the intravenous, intramuscular, subcutaneous, intraperitoneal, or intralymphatic route. Such formulations can be prepared using carriers, diluents or excipients familiar to one skilled in the art. In this regard, See, e.g. Remington's Pharmaceutical Sciences, 16th ed., 1980, Mack Publishing Company, edited by Osol et al. Such compositions may include proteins, such as serum proteins, for example, human serum albumin, buffers or buffering substances such as phosphates, other salts, or electrolytes, and the like. Suitable diluents may include, for example, sterile water, isotonic saline, dilute aqueous dextrose, a polyhydric alcohol or mixtures of such alcohols, for example, glycerin, propylene glycol, polyethylene glycol and the like. The compositions may contain preservatives such as phenethyl alcohol, methyl and propyl parabens, thimerosal, and the like. If desired, the composition can include about 0.05 to about .20 percent by weight of an antioxidant such as sodium metabisulfite or sodium bisulfite.

For intravenous administration, the composition preferably will be prepared so that the amount administered to the patient will be from about .01 to about 1 g of the conjugate. Preferably, the amount administered will be in the range of about .2 g to about 1 g of the conjugate. The conjugates of the invention are effective over a wide dosage range depending on factors such as the disease state to be treated or the biological effect to be modified, the manner in which the conjugate is administered, the age, weight and condition of the patient as well as other factors to be determined by the treating physician. Thus, the amount administered to any given patient must be determined on an individual basis.

- 41 -

One skilled in the art will appreciate that although specific reagents and reaction conditions are outlined in the following examples, modification can be made which are meant to be encompassed by the spirit and scope of the invention. The following preparations and examples, therefore, are provided to further illustrate the invention, and are not limiting.

EXAMPLES

EXAMPLE 1

Identification of the Semenogelin PSA Mediated Cleavage Site:

Liquefaction of the seminal gel parallels proteolytic fragmentation of semenogelin I [Lilja, H., Laurell, C.B., (1984) Scand. J. Clin. Lab. Inves. 44, 447-452]. It is believed that the proteolytic fragmentation of semenogelin is mainly due to the proteolytic activity of prostate-specific antigen [Lilja, H., (1985) J. Clin. Invest. 76, 1899-1903]. Utilizing the published sequence of semenogelin I [Lilja, H., Abrahamsson, P.A., Lundwall, A., (1989) J. of Biol. Chem. 264, 1894-1900] (Figure 1) we designed polymerase chain reaction primers to clone the semenogelin cDNA from a commercially available prostatic cDNA library (Clontech, Palo Alto, CA.). The purified semenogelin cDNA was placed into the bacterial expression vector pTAC [Linemeyer, D.L., Kelly, L.J., Minke, J.G., Gimenez-Gallego, G., DeSalvo, J. and Thomas, K.A., (1987) Bio/Technology 5, 960-965]. The semenogelin cDNA was designed so that a tubulin epitope was placed at the carboxyl end of semenogelin protein.. The bacterially expressed semenogelin protein was purified on an anti-tubulin antibody column. The purified semenogelin I protein was mixed with commercially prepared prostate-specific antigen (PSA) (York Biologicals International, Stony Brook, NY) in an 100 to 1 molar ratio (semenogelin I/PSA) in 12 mM Tris pH 8.0, 25 mM NaCl, 0.5 mM CaCl₂, and incubated for various times. The digest was fractionated by polyacrylamide gel electrophoresis and transferred by electrophoresis to ProBlott filter paper (Applied Biosystems, Inc., Foster City, CA.) in CAPS buffer [Matsudaira, P., (1987) J. Biol. Chem. 252,

- 42 -

10035-10038]. The ProBlott filter paper was stained with coomassie blue to identify the novel PSA generated semenogelin I protein fragments. The novel fragments were cut out of the filter with a scalpel and submitted for sequence determination. After the proteolytic fragments
5 were identified by variable time digestion, a 10 minute digestion reaction was performed. The affinity of PSA for the 5 potential cleavage sites in semenogelin I was determined to be as follows: site 349/350 > site 375/376 > site 289/290 = site 315/316 > site 159/160. The relative
10 affinities were derived from the coomassie blue staining intensity of each PSA generated peptide fragment. These intensities had approximate ratios of 3:1:0.6:0.3.

EXAMPLE 2

Preparation of Oligopeptides which Comprise the PSA Mediated 15 Cleavage Site:

Oligopeptides were prepared by solid-phase synthesis, using a double coupling protocol for the introduction of amino acids on the Applied Biosystems model 430A automated peptide synthesizer. Deprotection and removal of the oligopeptide from the resin support were achieved by
20 treatment with liquid hydrofluoric acid. The oligopeptides were purified by preparative high pressure liquid chromatography on reverse phase C18 silica columns using an aqueous 0.1% trifluoroacetic acid/acetonitrile gradient. Identity and homogeneity of the oligopeptides were confirmed by amino acid composition analysis, high pressure liquid
25 chromatography, and fast atom bombardment mass spectral analysis. The oligopeptides that were prepared by this method are shown in Figure 2.

EXAMPLE 3

Assessment of the Recognition of Oligopeptides by Free PSA :

30 The oligopeptides prepared as described in Example 2 were individually dissolved in PSA digestion buffer (12 mM tris(hydroxymethyl)-aminomethane pH8.0, 25 mM NaCl, 0.5 mM CaCl₂) and the solution added to PSA at a molar ration of 100 to 1. The reaction is quenched

- 43 -

after various reaction times by the addition of trifluoroacetic acid (TFA) to a final 1% (volume/volume). The quenched reaction was analyzed by HPLC on a reversed-phase C18 column using an aqueous 0.1%TFA/acetonitrile gradient. The results of the assessment are shown in Figure 2. Other oligopeptides prepared as described in Example 2 were tested in the same assay wherein the reaction was quenched at 4 hours. Those results of the assessment are shown in Figure 3. The removal of an asparagine residue from the amino terminus of the oligopeptide results in a significant loss of PSA mediated peptide hydrolysis, while the presence of a glutamic acid residue at the carboxyl end of the peptide appears not to be essential to recognition by PSA.

EXAMPLE 4


Preparation of Non-cleavable Oligopeptide-Doxorubicin Conjugates:

The derivatives of doxorubicin shown in Table 3 were prepared using the following general reaction: To a mixture of doxorubicin (Sigma) and the corresponding peptide (prepared by solid phase synthesis or commercially available (Sigma)) in DMSO was added HBTU and HOBt along with diisopropylethylamine and the reaction mixture was stirred overnight. The crude reaction mixture was purified directly by preparative HPLC on a reversed-phase C-18 column using a 0.1% trifluoroacetic acid (TFA) in acetonitrile/0.1% TFA in water gradient.

30

- 44 -

Table 3



15	<u>Compound</u>	<u>R</u>	<u>MS (parent ion)</u>
	12a	Ala-H	615
	12b	Ala-N-Ac	657
	12c	Ala-Ala-Ala-N-Ac	799.5
20	12d	Ala-Ser-Ala-Gly-Thr-Pro-Gly-Ala-N-Ac	1199
	(SEQ.ID.NO.: 12)		

EXAMPLE 5*In vitro Assay of Cytotoxicity of Peptidyl Derivatives of Doxorubicin:*

25 The cytotoxicities of the non-cleaveable oligopeptide-doxorubicin conjugates, prepared as described in Example 4, against a line of cells which is known to be killed by unmodified doxorubicin were assessed with an Alamar Blue assay. Specifically, cell cultures of LNCaP prostate tumor cells, which are a human metastatic prostate adenocarcinoma
 30 isolated from a needle biopsy of a lymph node (LNCaP.FGC: American Type Culture Collection, ATCC CRL 1740), or DuPRO cells in 96 well plates were diluted with medium containing various concentrations of a given conjugate (final plate well volume of 200 μ l). The cells were incubated for 3 days at 37°C and then 20 μ l of Alamar Blue was added to the assay well. The cells were further incubated and the assay plates

- 45 -

were read on a EL-310 ELISA reader at the dual wavelengths of 570 and 600 nm at 4 and 7 hours after addition of Alamar Blue. Relative percentage viability at the various concentration of conjugate tested was then calculated versus control (no conjugate) cultures. Cytotoxicities of unmodified doxorubicin and unmodified oligopeptide were also assessed. Figure 3 shows the cytotoxicity data for a representative compound (Compound 12d).

EXAMPLE 6

Assessment of Enzymatically Active PSA from LNCaP Cells

Enzymatic activity was demonstrated by incubating LNCaP serum free media (concentrated approximately 200 fold) with recombinant Semenogelin I protein. Approximately 0.5 µg of immunologically reactive PSA in concentrated conditioned media [determined by HYBRIDTECH (Tandem E) elisa] was mixed with approximately 3 µg of recombinant Semenogelin I and incubated for 4 hours at 37°C. At the end of the incubation, the digest mixture was analyzed by Western blot procedures. The results show that purified PSA from semen and PSA from LNCaP conditioned media generate identical proteolytic maps of the recombinant Semenogelin I protein. Thus, LNCaP cells produce enzymatically active PSA. LNCaP are tumorigenic in nude mice and produce detectable levels of circulating PSA.


EXAMPLE 7

Preparation of Cleavable Oligopeptide-Doxorubicin Conjugates:

The derivatives of doxorubicin wherein an oligopeptide which is proteolytically cleaved by free PSA is covalently attached to the amine of the sugar moiety of the doxorubicin were prepared using the following general reaction: To a mixture of doxorubicin (Sigma) and the corresponding peptide (prepared by solid phase synthesis as described in Example 2) in DMSO was added HBTU and HOBt along with diisopropylethylamine and the reaction mixture stirred overnight. The crude reaction mixture was purified directly by preparative HPLC on a

- 46 -

reversed-phase C-18 column using a 0.1% trifluoroacetic acid (TFA) in acetonitrile/0.1% TFA in water gradient. When reactive amine moieties were present on the peptide, such a functionality was typically protected as the fluorenylmethyloxycarbonyl adduct, which was removed by treatment with a secondary amine, such as piperidine and the like, subsequent to conjugation with doxorubicin. The instant conjugates have a structure of the general formula



and may be represented by the phrase "Ac-peptide-DOX (3)".
Conjugates prepared by this method are listed in Table 5 in Figure 5.

EXAMPLE 8

Assessment of the Recognition of Oligopeptide-Doxorubicin Conjugates by Free PSA :

The conjugates prepared as described in Example 7 were individually dissolved in PSA digestion buffer (12 mM tris(hydroxymethyl)-aminomethane pH8.0, 25 mM NaCl, 0.5 mM CaCl₂) and the solution added to PSA at a molar ratio of 100 to 1. The reaction is quenched after various reaction times by the addition of trifluoroacetic acid (TFA) to a final 1% (volume/volume). The quenched reaction was analyzed by HPLC on a reversed-phase C18 column using an aqueous

0.1%TFA/acetonitrile gradient. The results of the assessment are shown in Table 5 of Figure 5.

EXAMPLE 9

5 *Assessment of the Cleavage of Oligopeptide-Doxorubicin Conjugates in Cell Conditioned Media :*

Cell conditioned serum-free MEM α media (phenol red minus) was collected 3 days after the addition of the media to either LNCap or Dupro (prepared as described in *J. Urology*, 146:915-919 (1991)) cell lines. The media was concentrated 20 fold using an Amicon® Centriprep™ concentrator with a 10,000 molecular weight cutoff. The LNCap conditioned media contained free PSA protein at, on average, approximately 100 ng/mL concentration as determined by the Tandem®-E PSA immunodetection kit (Hybritech®). There was no detectable free PSA in the Dupro cell conditioned media.

100 μ L portions of concentrated conditioned media was mixed with 35 μ g of a oligopeptide-doxorubicin conjugate prepared as described in Example 7 and the mixture was incubated at 37°C for 0, 4 and 24 hour time points. The reactions were stopped by the addition of ZnCl₂ (to a 0.01M final concentration and analyzed by HPLC on a reversed-phase C18 column using an aqueous 0.1%TFA/acetonitrile gradient to determine the percentage of peptide-cytotoxic agent conjugate that had been digested. The results of the assessment are shown in Table 6 of Figure 6.

EXAMPLE 10

In vitro Assay of Cytotoxicity of Peptidyl Derivatives of Doxorubicin:

The cytotoxicities of the cleaveable oligopeptide-doxorubicin conjugates, prepared as described in Example 7, against a line of cells which is known to be killed by unmodified doxorubicin was assessed with an Alamar Blue assay as described in Example 5. Specifically, cell cultures of LNCap prostate tumor cells or DuPRO cells in 96 well plates was diluted with medium containing various concentrations of a given

- 48 -

conjugate (final plate well volume of 200 μ l). The cells were incubated for 3 days at 37°C, 20 μ l of Alamar Blue is added to the assay well. The cells were further incubated and the assay plates were read on a EL-310 ELISA reader at the dual wavelengths of 570 and 600 nm at 4 and 7
5 hours after addition of Alamar Blue. Relative percentage viability at the various concentration of conjugate tested was then calculated versus control (no conjugate) cultures. Cytotoxicities of the conjugates were also compared to the cytotoxicity of unmodified doxorubicin and
10 unmodified oligopeptide assessed in the same assay. Results of this assay are shown in Table 7 of Figure 7.

15

20

25

30

- 49 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: DeFeo-Jones, Deborah
Feng, Dong-Mei
Garsky, Victor M.
Jones, Raymond E.
Oliff, Allen I.
- (ii) TITLE OF INVENTION: NOVEL PEPTIDES
- (iii) NUMBER OF SEQUENCES: 146
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: DAVID A. MUTHARD
 - (B) STREET: 126 E. Lincoln Avenue, P.O. BOX 2000
 - (C) CITY: RAHWAY
 - (D) STATE: NEW JERSEY
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 07065
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Muthard, David A.
 - (B) REGISTRATION NUMBER: 35,297
 - (C) REFERENCE/DOCKET NUMBER: 19253Y
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (908)594-3903
 - (B) TELEFAX: (908)594-4720

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 462 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

- 50 -

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met	Lys	Pro	Asn	Ile	Ile	Phe	Val	Leu	Ser	Leu	Leu	Leu	Ile	Leu	Glu	1	5	10	15
Lys	Gln	Ala	Ala	Val	Met	Gly	Gln	Lys	Gly	Gly	Ser	Lys	Gly	Arg	Leu	20	25	30	
Pro	Ser	Glu	Phe	Ser	Gln	Phe	Pro	His	Gly	Gln	Lys	Gly	Gln	His	Tyr	35	40	45	
Ser	Gly	Gln	Lys	Gly	Lys	Gln	Gln	Thr	Glu	Ser	Lys	Gly	Ser	Phe	Ser	50	55	60	
Ile	Gln	Tyr	Thr	Tyr	His	Val	Asp	Ala	Asn	Asp	His	Asp	Gln	Ser	Arg	65	70	75	80
Lys	Ser	Gln	Gln	Tyr	Asp	Leu	Asn	Ala	Leu	His	Lys	Thr	Thr	Lys	Ser	85	90	95	
Gln	Arg	His	Leu	Gly	Gly	Ser	Gln	Gln	Leu	Leu	His	Asn	Lys	Gln	Glu	100	105	110	
Gly	Arg	Asp	His	Asp	Lys	Ser	Lys	Gly	His	Phe	His	Arg	Val	Val	Ile	115	120	125	
His	His	Lys	Gly	Gly	Lys	Ala	His	Arg	Gly	Thr	Gln	Asn	Pro	Ser	Gln	130	135	140	
Asp	Gln	Gly	Asn	Ser	Pro	Ser	Gly	Lys	Gly	Ile	Ser	Ser	Gln	Tyr	Ser	145	150	155	160
Asn	Thr	Glu	Glu	Arg	Leu	Trp	Val	His	Gly	Leu	Ser	Lys	Glu	Gln	Thr	165	170	175	
Ser	Val	Ser	Gly	Ala	Gln	Lys	Gly	Arg	Lys	Gln	Gly	Gly	Ser	Gln	Ser	180	185	190	
Ser	Tyr	Val	Leu	Gln	Thr	Glu	Glu	Leu	Val	Ala	Asn	Lys	Gln	Gln	Arg	195	200	205	
Glu	Thr	Lys	Asn	Ser	His	Gln	Asn	Lys	Gly	His	Tyr	Gln	Asn	Val	Val	210	215	220	
Glu	Val	Arg	Glu	Glu	His	Ser	Ser	Lys	Val	Gln	Thr	Ser	Leu	Cys	Pro	225	230	235	240
Ala	His	Gln	Asp	Lys	Leu	Gln	His	Gly	Ser	Lys	Asp	Ile	Phe	Ser	Thr	245	250	255	

- 51 -

Gln Asp Glu Leu Leu Val Tyr Asn Lys Asn Gln His Gln Thr Lys Asn
 260 265 270
 Leu Asn Gln Asp Gln Gln His Gly Arg Lys Ala Asn Lys Ile Ser Tyr
 275 280 285
 Gln Ser Ser Ser Thr Glu Glu Arg Arg Leu His Tyr Gly Glu Asn Gly
 290 295 300
 Val Gln Lys Asp Val Ser Gln Ser Ser Ile Tyr Ser Gln Thr Glu Glu
 305 310 315 320
 Lys Ala Gln Gly Lys Ser Gln Lys Gln Ile Thr Ile Pro Ser Gln Glu
 325 330 335
 Gln Glu His Ser Gln Lys Ala Asn Lys Ile Ser Tyr Gln Ser Ser Ser
 340 345 350
 Thr Glu Glu Arg Arg Leu His Tyr Gly Glu Asn Gly Val Gln Lys Asp
 355 360 365
 Val Ser Gln Arg Ser Ile Tyr Ser Gln Thr Glu Lys Leu Val Ala Gly
 370 375 380
 Lys Ser Gln Ile Gln Ala Pro Asn Pro Lys Gln Glu Pro Trp His Gly
 385 390 395 400
 Glu Asn Ala Lys Gly Glu Ser Gly Gln Ser Thr Asn Arg Glu Gln Asp
 405 410 415
 Leu Leu Ser His Glu Gln Lys Gly Arg His Gln His Gly Ser His Gly
 420 425 430
 Gly Leu Asp Ile Val Ile Ile Glu Gln Glu Asp Asp Ser Asp Arg His
 435 440 445
 Leu Ala Gln His Leu Asn Asn Asp Arg Asn Pro Leu Phe Thr
 450 455 460

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 52 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Gly	Lys	Gly	Ile	Ser	Ser	Gln	Tyr	Ser	Asn	Thr	Glu	Glu	Arg	Leu
1				5				10						15

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10	

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Gly	Glu	Asn	Gly	Val	Gln	Lys	Asp	Val	Ser	Gln	Arg	Ser	Ile	Tyr	Ser
1				5					10					15	

Gln Thr Glu

- 53 -

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gln Ser Ser Ile Tyr Ser
1 5 10 15
Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Gly Arg Lys Ala Asn Lys Ile Ser Tyr Gln Ser Ser Ser Thr Glu Glu
1 5 10 15
Arg Arg Leu His Tyr Gly Glu Asn Gly
 20 25

(2) INFORMATION FOR SEQ ID NO:7:

- 54 -

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Ser Tyr Gln Ser Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Ile Ser Tyr Gln Ser Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- 55 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 56 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Ala Asn Lys Ile Ser Tyr Gln Ser Ser Ser Thr Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Ala Ser Ala Gly Thr Pro Gly Ala
1 5

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Asn Lys Ile Ser Tyr Gln Ser
1 5

(2) INFORMATION FOR SEQ ID NO:14:

- 57 -

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Lys Ile Ser Tyr Gln Ser
1 5

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 12
(D) OTHER INFORMATION: /note= "any natural amino acid"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gln Xaa Ser Ile Tyr Ser
1 5 10 15

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:16:

- 58 -

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Asn Lys Ile Ser Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Asn Lys Ile Ser Tyr Gln Ser Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- 59 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser
1				5					10

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 60 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Gln Leu Asp Asn Lys Ile Ser Tyr Gln Ser Ser Ser Thr His Gln Ser
1 5 10 15
Ser

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Asn Arg Ile Ser Tyr Gln Ser
1 5

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Asn Lys Val Ser Tyr Gln Ser
1 5

- 61 -

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Asn Lys Met Ser Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Asn Lys Leu Ser Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 62 -

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Asn Lys Ile Thr Tyr Gln Ser Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Asn Lys Ile Ser Phe Gln Ser Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

- 63 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Asn	Lys	Ile	Ser	Trp	Gln	Ser	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Asn	Lys	Ile	Ser	Tyr	Asn	Ser	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Asn	Lys	Ile	Ser	Tyr	Gln	Thr	Ser	Ser	Thr
1				5					10

- 64 -

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Asn Lys Ile Ser Tyr Gln Ser
1 5

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Gln Lys Ile Ser Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 65 -

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Asn Arg Ile Thr Tyr Gln Ser Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Asn Arg Ile Ser Phe Gln Ser Ser Ser Thr
1 5 10

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

- 66 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Gln Lys Ile Ser Tyr Gln Thr Ser Ser Thr
1 5 10

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Asn Arg Ile Ser Trp Gln Ser Ser Ser Thr
1 5 10

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Asn Arg Ile Ser Tyr Gln Thr Ser Ser Thr
1 5 10

- 67 -

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Asn	Lys	Ile	Thr	Tyr	Gln	Thr	Ser	Ser	Thr
1			5						10

(2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Asn	Lys	Leu	Ser	Tyr	Gln	Thr	Ser	Ser	Thr
1			5						10

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

- 68 -

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Gln	Lys	Leu	Ser	Tyr	Gln	Ser	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Asn	Arg	Leu	Ser	Tyr	Gln	Thr	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:41:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

- 69 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Asn	Lys	Val	Ser	Phe	Gln	Ser	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:42:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Asn	Arg	Val	Ser	Trp	Gln	Ser	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:43:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Gln	Lys	Val	Ser	Tyr	Gln	Ser	Ser	Ser	Thr
1				5					10

- 70 -

(2) INFORMATION FOR SEQ ID NO:44:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr
1					5				10

(2) INFORMATION FOR SEQ ID NO:45:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Gly	Glu	Gln	Gly	Val	Gln	Lys	Asp	Val	Ser	Gln	Ser	Ser	Ile	Tyr	Ser
1				5					10					15	

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:46:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids

- 71 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Gly	Lys	Gly	Ile	Ser	Ser	Gln	Tyr	Ser	Asn	Thr	Asp	Glu	Arg	Leu
1				5				10						15

(2) INFORMATION FOR SEQ ID NO:47:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

Gly	Glu	Asn	Gly	Leu	Gln	Lys	Asp	Val	Ser	Gln	Ser	Ser	Ile	Tyr	Ser
1				5					10					15	

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:48:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- 72 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Gly	Glu	Asn	Gly	Val	Asn	Lys	Asp	Val	Ser	Gln	Ser	Ser	Ile	Tyr	Ser
1				5					10					15	

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:49:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

Gly	Glu	Asn	Gly	Val	Gln	Arg	Asp	Val	Ser	Gln	Arg	Ser	Ile	Tyr	Ser
1				5					10					15	

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:50:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

- 73 -

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Gly	Glu	Asn	Gly	Val	Gln	Lys	Asp	Val	Ser	Gln	Lys	Ser	Ile	Tyr	Ser
1				5					10					15	

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:51:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Gly	Glu	Asn	Gly	Val	Gln	Lys	Asp	Leu	Ser	Gln	Thr	Ser	Ile	Tyr	Ser
1				5					10					15	

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:52:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- 74 -

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gln Ser Ser Ile Phe Ser
1 5 10 15
Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Gly Glu Asn Gly Val Gln Lys Asp Met Ser Gln Ser Ser Ile Tyr Thr
1 5 10 15
Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 75 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Gly	Glu	Asn	Gly	Val	Gln	Lys	Asp	Val	Ser	Gln	Arg	Ser	Ile	Tyr	Thr
1				5					10					15	

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:55:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Gly	Glu	Asn	Gly	Val	Gln	Lys	Asp	Val	Ser	Gln	Ser	Ser	Ile	Tyr	Ser
1				5					10					15	

Gln Ser Glu

(2) INFORMATION FOR SEQ ID NO:56:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 76 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

Gly	Glu	Asn	Gly	Val	Gln	Lys	Asp	Val	Ser	Gln	Arg	Ser	Ile	Tyr	Ser
1				5					10					15	

Asn Thr Glu

(2) INFORMATION FOR SEQ ID NO:57:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

Gly	Lys	Ala	Ile	Ser	Ser	Gln	Tyr	Ser	Asn	Thr	Glu	Glu	Arg	Leu
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:58:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

Gly	Lys	Gly	Ile	Ser	Ser	Gln	Tyr	Ser	Asn	Ser	Glu	Glu	Arg	Leu
1				5					10					15

- 77 -

(2) INFORMATION FOR SEQ ID NO:59:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Gly	Arg	Gly	Ile	Ser	Ser	Gln	Tyr	Ser	Asn	Thr	Glu	Glu	Arg	Leu
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:60:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

Gly	Lys	Gly	Ile	Thr	Ser	Gln	Tyr	Ser	Asn	Thr	Glu	Glu	Arg	Leu
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:61:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 78 -

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

Gly	Lys	Gly	Ile	Ser	Thr	Gln	Tyr	Ser	Asn	Thr	Glu	Glu	Arg	Leu
1				5				10						15

(2) INFORMATION FOR SEQ ID NO:62:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

Gly	Lys	Gly	Ile	Ser	Ser	Asn	Tyr	Ser	Asn	Thr	Glu	Glu	Arg	Leu
1				5				10						15

(2) INFORMATION FOR SEQ ID NO:63:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

- 79 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

Ala	Lys	Gly	Ile	Ser	Ser	Gln	Tyr	Ser	Asn	Thr	Glu	Glu	Arg	Leu
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:64:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

Gly	Lys	Gly	Ile	Ser	Ser	Gln	Phe	Ser	Asn	Thr	Glu	Glu	Arg	Leu
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:65:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

Gly	Lys	Gly	Ile	Ser	Ser	Gln	Tyr	Thr	Asn	Ser	Glu	Glu	Arg	Leu
1				5					10					15

- 80 -

(2) INFORMATION FOR SEQ ID NO:66:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

Gly	Lys	Gly	Ile	Ser	Ser	Gln	Tyr	Ser	Asn	Ser	Glu	Glu	Arg	Leu
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:67:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

Ser	Gln	Lys	Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu	Glu
1				5					10					15	

Arg	Arg	Leu	His	Tyr	Gly	Glu	Asn	Gly
			20					25

(2) INFORMATION FOR SEQ ID NO:68:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids

- 81 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

Ile Ser Tyr Gln Ser Ser Ser Thr
1 5

(2) INFORMATION FOR SEQ ID NO:69:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

Ala Asn Lys Ile Ser Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:70:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO

- 82 -

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Leu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

Ala	Asn	Gly	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

Ala Asn Pro Ile Ser Tyr Gln Ser Ser Ser Thr Glu
1 5 10

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(v) FRAGMENT TYPE: internal

Ala Asn Lys Ile Ser Tyr Gln Ser Ala Ser Thr Glu
1 5 10

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(v) FRAGMENT TYPE: internal

Ala Asn Lys Ile Ser Tyr Gln Ser Ser Lys Thr Glu
-1 - - - - -5 - - - - -10 - - - - -

BNSDOCID: <WO__9600503A1_IA>

- 84 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Thr	Glu
1				5					10	

(2) INFORMATION FOR SEQ ID NO:76:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

- (A) NAME/KEY: Peptide
 - (B) LOCATION: 5
 - (D) OTHER INFORMATION: /label= d-serine
- /note= "unnatural configuration of the amino acid"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5						10	

(2) INFORMATION FOR SEQ ID NO:77:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single

- 85 -

- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (ix) FEATURE:
- (A) NAME/KEY: Peptide
 - (B) LOCATION: 4
 - (D) OTHER INFORMATION: /label= d-isoleucine
- /note= "unnatural amino acid stereochemical configuration"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:78:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Gln	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:79:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- 86 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ala	Lys	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:80:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 3

(D) OTHER INFORMATION: /label= d-lysine

/note= "unnatural amino acid stereochemical configuration"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:81:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

- 87 -

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Thr	Glu
1			5						10

(2) INFORMATION FOR SEQ ID NO:82:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

Ala	Asn	Lys	Ser	Tyr	Gln	Ser	Ser	Thr	Glu
1			5						10

(2) INFORMATION FOR SEQ ID NO:83:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

- 88 -

Ala Asn Lys Ile Tyr Gln Ser Ser Thr Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:84:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

Ala Asn Lys Ala Ser Tyr Gln Ser Ala Ser Thr Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:85:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

Ala Asn Glu Ile Ser Tyr Gln Ser Ala Ser Thr Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:86:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids

- 89 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

Lys Ile Ser Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:87:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

Ser Tyr Gln Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:88:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

- 90 -

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

Ser Tyr Gln Ser Ser Thr Leu
1 5

(2) INFORMATION FOR SEQ ID NO:89:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

Ala Ser Tyr Gln Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:90:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

- 91 -

(2) INFORMATION FOR SEQ ID NO:91:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

Ala Asn Glu Ile Ser Tyr Gln Ser Ser Ser Thr Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:92:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

Ala Asn Lys Ile Ser Tyr Tyr Ser Ser Ser Thr Glu
-1- - - - -5- - - - -10- - - - -

(2) INFORMATION FOR SEO ID NO:93:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids

- 92 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

Ala	Asn	Lys	Ile	Ser	Tyr	Tyr	Ser	Ala	Ser	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:94:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

Ala	Ser	Tyr	Gln	Ser	Ser	Leu
1				5		

(2) INFORMATION FOR SEQ ID NO:95:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

- 93 -

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

Ala	Asn	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10

(2) INFORMATION FOR SEQ ID NO:96:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

Ala	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5				

(2) INFORMATION FOR SEQ ID NO:97:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

- 94 -

Ser Tyr Gln Ser Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:98:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

Ala Asn Lys Ala Ser Tyr Gln Ser Ala Ser Cys
1 5 10

(2) INFORMATION FOR SEQ ID NO:99:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

Gln Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:100:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids

- 95 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

Tyr Gln Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:101:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

Ser Gln Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:102:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

- 96 -

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

Ala	Asn	Lys	Ile	Ser	Gln	Ser	Ser	Thr	Glu
1			5						10

(2) INFORMATION FOR SEQ ID NO:103:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 3

(D) OTHER INFORMATION: /label= unnatural
/note= "ornithine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

Ala	Asn	Xaa	Ile	Ser	Tyr	Gln	Ser	Ser	Thr	Glu
1			5							10

(2) INFORMATION FOR SEQ ID NO:104:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 97 -

(ix) FEATURE:

(A) NAME/KEY: Peptide
(B) LOCATION: 2
(D) OTHER INFORMATION: /label= unnatural
/note= "3,4-dichlorophenalanine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

Ser Xaa Gln Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:105:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

(A) NAME/KEY: Peptide
(B) LOCATION: 2
(D) OTHER INFORMATION: /label= unnatural
/note= "(3-pyridinyl)alanine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

Ser Xaa Gln Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:106:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- 98 -

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

Ser Lys Gln Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:107:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

Ser Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:108:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

(A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /label= unnatural

- 99 -

/note= "epsilon aminocaproic acid"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

Xaa Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:109:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

(A) NAME/KEY: Peptide
(B) LOCATION: 4
(D) OTHER INFORMATION: /label= unnatural

/note= "N-methylisoleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

Ala Asn Lys Xaa Ser Tyr Gln Ser Ser Thr Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:110:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 100 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

Ser Tyr Gln Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:111:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

Tyr Gln Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

Ser Tyr Lys Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:113:

(i) SEQUENCE CHARACTERISTICS:

- 101 -

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

Ser Tyr Tyr Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:114:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

Ser Tyr Gln Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:115:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

- 102 -

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

Ser Tyr Gln Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:116:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

(A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /label= unnatural
/note= "2,3-diaminopropionic acid"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

Xaa Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:117:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- 103 -

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr
1				5					10	

(2) INFORMATION FOR SEQ ID NO:118:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

Ala	Asn	Lys	Ala	Ser	Tyr	Gln	Ser	Ala	Ser	Thr	Leu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:119:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

Ala	Asn	Lys	Ala	Ser	Tyr	Gln	Ser	Ala	Ser	Leu
1				5					10	

- 104 -

(2) INFORMATION FOR SEQ ID NO:120:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

Ala	Asn	Lys	Ala	Ser	Tyr	Gln	Ser	Ser	Ser	Leu
1				5						10

(2) INFORMATION FOR SEQ ID NO:121:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

Ala	Asn	Lys	Ala	Ser	Tyr	Gln	Ser	Ser	Leu
1				5					10

(2) INFORMATION FOR SEQ ID NO:122:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 105 -

(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(v) FRAGMENT TYPE: internal

(ix) FEATURE:
 (A) NAME/KEY: Peptide
 (B) LOCATION: 7
 (D) OTHER INFORMATION: /label= d-leucine
/note= "unnatural amino acid stereochemical configuration"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

Ser Tyr Gln Ser Ser Thr Leu
1 5

(2) INFORMATION FOR SEQ ID NO:123:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

Ala Asn Lys Ala Ser Tyr Ala Ser Ser Ser Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:124:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- 106 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

Lys	Tyr	Gln	Ser	Ser	Ser	Ser
1				5		

(2) INFORMATION FOR SEQ ID NO:125:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

Ser	Tyr	Gln	Ser	Ser	Lys	Leu
1				5		

(2) INFORMATION FOR SEQ ID NO:126:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

- 107 -

(A) NAME/KEY: Peptide
(B) LOCATION: 7
(D) OTHER INFORMATION: /label= d-leucine
/note= "unnatural amino acid stereochemical configuration"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

Ser Tyr Gln Ser Ser Lys Leu
1 5

(2) INFORMATION FOR SEQ ID NO:127:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

Asn Lys Ile Ser Tyr Tyr Ser
1 5

(2) INFORMATION FOR SEQ ID NO:128:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

- 108 -

Asn Lys Ala Ser Tyr Gln Ser
1 5

(2) INFORMATION FOR SEQ ID NO:129:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

Ser Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:130:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

Asn Lys Ile Ser Tyr Gln Ser Ala
1 5

(2) INFORMATION FOR SEQ ID NO:131:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid

- 109 -

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

Ala Asn Lys Ile Ser Tyr Tyr Ser
1 5

(2) INFORMATION FOR SEQ ID NO:132:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

Ala Asn Lys Ala Ser Tyr Gln Ser
1 5

(2) INFORMATION FOR SEQ ID NO:133:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- 110 -

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

Ser Tyr Gln Ser Ser Thr
1 5

(2) INFORMATION FOR SEQ ID NO:134:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

Ser Tyr Gln Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:135:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

- 111 -

Ser Tyr Gln Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:136:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

Ala Asn Lys Ile Ser Tyr Gln Ser Ala
1 5

(2) INFORMATION FOR SEQ ID NO:137:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

Ala Asn Lys Ile Ser Tyr Tyr Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:138:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid

- 112 -

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

Ala Asn Lys Ile Ser Tyr Tyr Ser Ala
1 5

(2) INFORMATION FOR SEQ ID NO:139:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

Ala Asn Lys Ala Ser Tyr Gln Ser Ala
1 5

(2) INFORMATION FOR SEQ ID NO:140:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- 113 -

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

Lys Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:141:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

(A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /label= homoarginine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

Xaa Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:142:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 114 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

Lys Tyr Gln Ser Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:143:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /label= homoarginine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

Xaa Tyr Gln Ser Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:144:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

- 115 -

Ser Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:145:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /label= homoarginine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

Xaa Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:146:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 7
(D) OTHER INFORMATION: /label= norleucine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

Lys Tyr Gln Ser Ser Ser Leu
1 5

- 116 -

WHAT IS CLAIMED IS:

1. An oligopeptide that comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen.
5
2. The oligopeptide according to Claim 1 wherein the sequence of amino acids is
 - 10 a) AsnLysIleSerTyrGln|Ser (SEQ.ID.NO.: 13),
 - b) LysIleSerTyrGln|Ser (SEQ.ID.NO.: 14),
 - c) GlyGluAsnGlyValGlnLysAspValSerGlnXaaSerIleTyr|SerGlnThrGlu
15 (SEQ.ID.NO.: 15) ,
 - d) GlyLysGlyIleSerSerGlnTyr|SerAsnThrGluGluArgLeu
(SEQ.ID.NO.: 2),
 - 20 e) AsnLysIleSerTyrTyr|Ser (SEQ.ID.NO.: 127),
 - f) AsnLysAlaSerTyrGln|Ser (SEQ.ID.NO.: 128),
 - 25 g) SerTyrGln|SerSer (SEQ.ID.NO.: 129);
 - h) LysTyrGln|SerSer (SEQ.ID.NO.: 140); or
 - i) hArgTyrGln|SerSer (SEQ.ID.NO.: 141);
- 30 wherein hArg is homoarginine and Xaa is any natural amino acid.
3. The oligopeptide according to Claim 2 wherein the sequence of amino acids is

- 117 -

- a) AsnLysIleSerTyrGln|SerSer (SEQ.ID.NO.: 16),
- b) AsnLysIleSerTyrGln|SerAla (SEQ.ID.NO.: 130),
- 5 c) AsnLysIleSerTyrGln|SerSerSer (SEQ.ID.NO.: 17),
- d) AlaAsnLysIleSerTyrGln|SerSerSer (SEQ.ID.NO.: 18),
- 10 e) LysIleSerTyrGln|SerSerSerThrGlu (SEQ.ID.NO.: 19),
- f) GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyr|SerGlnThrGlu
(SEQ.ID.NO.: 4),
- 15 g) GlyGluAsnGlyValGlnLysAspValSerGlnSerSerIleTyr|SerGlnThrGlu
(SEQ.ID.NO.: 5),
- h) AlaAsnLysIleSerTyrTyr|Ser (SEQ.ID.NO.: 131),
- 20 i) AlaAsnLysAlaSerTyrGln|Ser (SEQ.ID.NO.: 132),
- j) SerTyrGln|SerSerThr (SEQ.ID.NO.: 133),
- k) SerTyrGln|SerSerSer (SEQ.ID.NO.: 134),
- 25 l) LysTyrGln|SerSerSer (SEQ.ID.NO.: 142),
- m) hArgTyrGln|SerSerSer (SEQ.ID.NO.: 143), or
- 30 n) SerTyrGln|SerSerLeu (SEQ.ID.NO.: 135).

4. The oligopeptide according to Claim 2 wherein the amino acid sequence is

- 118 -

- a) AsnLysIleSerTyrGln|SerSerSerThr (SEQ.ID.NO.: 10),
b) AlaAsnLysIleSerTyrGln|SerAla (SEQ.ID.NO.: 136),
5 c) AsnLysIleSerTyrGln|SerSerSerThrGlu (SEQ.ID.NO.:3),
d) AlaAsnLysIleSerTyrGln|SerSerSerThrGlu (SEQ.ID.NO.: 11),
10 e) GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyr|SerGlnThrGlu
(SEQ.ID.NO.: 4),
f) AlaAsnLysIleSerTyrTyr|SerSer (SEQ.ID.NO.: 137),
g) AlaAsnLysIleSerTyrTyr|SerAla (SEQ.ID.NO.: 138),
15 h) AlaAsnLysAlaSerTyrGln|SerAla (SEQ.ID.NO.: 139), or
i) AlaSerTyrGln|SerSerLeu (SEQ.ID.NO.: 94).

20 5. The oligopeptide according to Claim 2 wherein the amino acid sequence is

- a) GlyArgLysAlaAsnLysIleSerTyrGln|SerSerSerThrGluGluArgArg
25 LeuHisTyr GlyGluAsnGly (SEQ.ID.NO.: 6).

6. The oligopeptide according to Claim 1 which is selected from:

- 30 AsnArgIleSerTyrGln|Ser (SEQ.ID.NO.: 21),
AsnLysValSerTyrGln|Ser (SEQ.ID.NO.: 22),
AsnLysMetSerTyrGln|SerSer (SEQ.ID.NO.: 23),
AsnLysLeuSerTyrGln|SerSer (SEQ.ID.NO.: 24),
AsnLysIleThrTyrGln|SerSerSer (SEQ.ID.NO.: 25),

- 119 -

- AsnLysIleSerPheGln|SerSerSer (SEQ.ID.NO.: 26),
 AsnLysIleSerTrpGln|SerSerSerThr (SEQ.ID.NO.: 27),
 AsnLysIleSerTyrAsn|SerSerSerThr (SEQ.ID.NO.: 28),
 AsnLysIleSerTyrGln|ThrSerSerThr (SEQ.ID.NO.: 29),
 5 AsnLysIleSerTyrGln|Ser (SEQ.ID.NO.: 30),
 GlnLysIleSerTyrGln|SerSer (SEQ.ID.NO.: 31),
 AsnArgIleThrTyrGln|SerSerSer (SEQ.ID.NO.: 32),
 AsnArgIleSerPheGln|SerSerSerThr (SEQ.ID.NO.: 33),
 AsnArgIleSerTrpGln|SerSerSerThr (SEQ.ID.NO.: 35),
 10 AsnArgIleSerTyrGln|ThrSerSerThr (SEQ.ID.NO.: 36),
 AsnLysIleThrTyrGln|ThrSerSerThr (SEQ.ID.NO.: 37),
 AsnLysLeuSerTyrGln|ThrSerSerThr (SEQ.ID.NO.: 38),
 GlnLysLeuSerTyrGln|SerSerSerThr (SEQ.ID.NO.: 39),
 AsnArgLeuSerTyrGln|ThrSerSerThr (SEQ.ID.NO.: 40),
 15 AsnLysValSerPheGln|SerSerSerThr (SEQ.ID.NO.: 41),
 AsnArgValSerTrpGln|SerSerSerThr (SEQ.ID.NO.: 42),
 GlnLysValSerTyrGln|SerSerSerThr (SEQ.ID.NO.: 43),
 GlnLysIleSerTyrGln|ThrSerSerThr (SEQ.ID.NO.: 34), or
 AsnLysIleSerTyrGln|SerSerSerThr (SEQ.ID.NO.: 44).
 20

7. The oligopeptide according to Claim 1 which is

- AlaAsnLysIleSerTyrGln|SerSerSerThrGlu-amide (SEQ.ID.NO.: 11)
 Ac-AlaAsnLysIleSerTyrGln|SerSerSerThrLeu (SEQ.ID.NO.: 70)
 25
 Ac-AlaAsnLysIleSerTyrGln|SerSerSerThrGlu-amide (SEQ.ID.NO.: 11)
 Ac-AlaAsnLysIleSerTyrGln|SerSerSerThrLeu-amide (SEQ.ID.NO.: 70)
 Ac-AlaAsnLysIleSerTyrGln|SerAlaSerThrGlu-amide (SEQ.ID.NO.: 73)
 Ac-AlaAsnLysIleSerTyrGln|SerSerLysThrGlu-amide (SEQ.ID.NO.: 74)
 30 Ac-AlaAsnLysIleSerTyrGln|SerSerThrGlu-amide (SEQ.ID.NO.: 75)
 Ac-AlaAsnLysIleSerTyrGln|SerSerGlnThrGlu-amide (SEQ.ID.NO.: 78)
 Ac-AlaAsnLysIleSerTyrGln|SerAlaLysThrGlu-amide (SEQ.ID.NO.: 79)
 Ac-AlaAsnLysIleSerTyrGln|SerThrGlu-amide (SEQ.ID.NO.: 81)
 Ac-AlaAsnLysSerTyrGln|SerSerThrGlu-amide (SEQ.ID.NO.: 82)

- 120 -

- Ac-AlaAsnLysAlaSerTyrGln|SerAlaSerThrGlu-amide (SEQ.ID.NO.: 84)
- Ac-AlaAsnGluIleSerTyrGln|SerAlaSerThrGlu-amide (SEQ.ID.NO.: 85)
- Ac-AsnLysIleSerTyrGln|SerSer-amide (SEQ.ID.NO.: 16)
- 5 Ac-LysIleSerTyrGln|SerSer-amide (SEQ.ID.NO.: 86)
- Ac-SerTyrGln|SerSerThrGlu-amide (SEQ.ID.NO.: 87)
- Ac-AlaSerTyrGln|SerSerThrGlu-amide (SEQ.ID.NO.: 89)
- Ac-AlaAsnLysIleSerTyrTyr|SerSerSerThrGlu-amide (SEQ.ID.NO.: 92)
- Ac-AlaAsnLysIleSerTyrTyr|SerAlaSerThrGlu-amide (SEQ.ID.NO.: 93)
- 10 Ac-AlaSerTyrGln|SerSerLeu-amide (SEQ.ID.NO.: 94)
- Ac-AlaAsnSerTyrGln|SerSerSerThrGlu-amide (SEQ.ID.NO.: 95)
- Ac-AlaSerTyrGln|SerSerSerThrGlu-amide (SEQ.ID.NO.: 96)
- Ac-SerTyrGln|SerSerSerThrGlu-amide (SEQ.ID.NO.: 97) or
- 15 Ac-AlaAsnLysAlaSerTyrGln|SerAlaSerCys-amide (SEQ.ID.NO.: 98).

8. An assay for determining proteolytic activity of free prostate specific antigen in a sample, comprising the steps of:
- (a), reacting a substrate, wherein the substrate is an oligopeptide that comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen, with the sample; and
- 20 (b), detecting whether the substrate has been cleaved.
9. The assay according to Claim 8 wherein the step of detecting whether the substrate has been cleaved comprises analyzing the assay mixture by high performance liquid chromatography.
10. An assay for identifying compounds which inhibit the proteolytic activity of prostate specific antigen, comprising:
- 30 (a), reacting a substrate, wherein the substrate comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen, with free prostate

- 121 -

specific antigen in the presence of a test substance;
and

- (b), detecting whether the substrate has been cleaved,
in which the ability of the test substance to inhibit
proteolytic activity of prostate specific antigen is
indicated by a decrease in the cleavage of the
substrate as compared to the cleavage of the substrate
in the absence of the test substance.

11. The assay according to Claim 10 wherein the step of
detecting whether the substrate has been cleaved comprises analyzing the
assay mixture by high performance liquid chromatography.

12. A conjugate which is useful for the treatment of
prostate cancer which comprises a cytotoxic agent attached to a
oligopeptide, wherein the oligopeptide comprises a sequence of amino
acids that is recognized and selectively proteolytically cleaved by free
prostate specific antigen, wherein the means of attachment is a covalent
bond or a chemical linker.

13. The conjugate according to Claim 12 wherein the
cytotoxic agent is a member of a class of cytotoxic agents selected from
the following classes:

- a) anthracycline family of drugs,
- b) the vinca alkaloid drugs,
- c) the mitomycins,
- d) the bleomycins,
- e) the cytotoxic nucleosides,
- f) the pteridine family of drugs,
- g) diynenes,
- h) estramustine,
- i) cyclophosphamide, and
- h) the podophyllotoxins.

- 122 -

14. The conjugate according to Claim 12 wherein the cytotoxic agent is selected from the following cytotoxic agents:


- a) doxorubicin,
- b) carminomycin,
- 5 c) daunorubicin,
- d) aminopterin,
- e) methotrexate,
- f) methopterin,
- g) dichloro-methotrexate,
- 10 h) mitomycin C,
- i) porfiromycin,
- j) 5-fluorouracil,
- k) 6-mercaptopurine,
- l) cytosine arabinoside,
- 15 m) podophyllotoxin,
- n) etoposide,
- o) etoposide phosphate,
- p) melphalan,
- q) vinblastine,
- 20 r) vincristine,
- s) leurosine,
- t) vindesine,
- u) estramustine,
- v) cisplatin,
- 25 w) cyclophosphamide, and
- x) leurosine.

15. The conjugate according to Claim 12 wherein the cytotoxic agent is selected from doxorubicin and vinblastine or a
30 cytotoxic derivative thereof.

16. The conjugate according to Claim 12 wherein the cytotoxic agent is doxorubicin or a cytotoxic derivative thereof.

- 123 -

17. The conjugate according to Claim 16 of the formula I:



wherein:

oligopeptide is an oligopeptide which is specifically recognized by the free prostate specific antigen (PSA) and is capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen;

X_L is absent or is an amino acid selected from:

- 25
- a) phenylalanine,
 - b) leucine,
 - c) valine,
 - d) isoleucine,
 - e) (2-naphthyl)alanine,
 - 30 f) cyclohexylalanine,
 - g) diphenylalanine,
 - h) norvaline, and
 - j) norleucine;

R is hydrogen or $-(C=O)R^1$; and

- 124 -

R¹ is C₁-C₆-alkyl or aryl.

18. The conjugate according to Claim 17 wherein:

5

oligopeptide is an oligomer that comprises an amino acid sequence selected from:

10

a) AsnLysIleSerTyrGln|Ser (SEQ.ID.NO.: 13),

b) LysIleSerTyrGln|Ser (SEQ.ID.NO.: 14),

15

c) GlyGluAsnGlyValGlnLysAspValSerGlnXaaSerIleTyr|SerGlnThrGlu (SEQ.ID.NO.: 15),

d) GlyLysGlyIleSerSerGlnTyr|SerAsnThrGluGluArgLeu (SEQ.ID.NO.: 2),

20

e) AsnLysIleSerTyrTyr|Ser (SEQ.ID.NO.: 127),

f) AsnLysAlaSerTyrGln|Ser (SEQ.ID.NO.: 128),

g) SerTyrGln|SerSer (SEQ.ID.NO.: 129), and

25

h) hArgTyrGln|SerSer (SEQ.ID.NO.: 141);

wherein hArg is homoarginine and Xaa is any natural amino acid;

30

X_L is absent or is an amino acid selected from:

a) leucine,

b) isoleucine, and

d) valine; and

R is acetyl, pivaloyl or benzoyl.


- 125 -

19. The conjugate according to Claim 16 which is selected from:

5

10

15




wherein X is:


20

25

30




- 126 -



20. The conjugate according to Claim 15 of the formula
 II:

- 127 -



wherein:

oligopeptide is an oligopeptide which is specifically recognized by the free prostate specific antigen (PSA) and is capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen.

1: MetLysProAsnIleIlePheValLeuSerLeuLeuLeuIleLeuGluLysGlnAlaAla -
21: ValMetGlyGlnLysGlyGlySerLysGlyArgLeuProSerGluPheSerGlnPhePro -
41: HisGlyGlnLysGlyGlnHisTyrSerGlyGlnLysGlyLysGlnGlnThrGluSerLys -
61: GlySerPheSerIleGlnTyrThrTyrHisValAspAlaAsnAspHisAspGlnSerArg -
81: LysSerGlnGlnTyrAspLeuAsnAlaLeuHisLysThrThrLysSerGlnArgHisLeu -
101: GlyGlySerGlnGlnLeuLeuHisAsnLysGlnGluGlyArgAspHisAspLysSerLys -
121: GlyHisPheHisArgValValIleHisHisLysGlyGlyLysAlaHisArgGlyThrGln -
141: AsnProSerGlnAspGlnGlyAsnSerProSerGlyLysGlyIleSerSerGlnTyr|Ser - CS#5
161: AsnThrGluGluArgLeuTrpValHisGlyLeuSerLysGluGlnThrSerValSerGly -
181: AlaGlnLysGlyArgLysGlnGlyGlySerGlnSerSerTyrValLeuGlnThrGluGlu -
201: LeuValAlaAsnLysGlnGlnArgGluThrLysAsnSerHisGlnAsnLysGlyHisTyr -
221: GlnAsnValValGluValArgGluGluHisSerSerLysValGlnThrSerLeuCysPro -
241: AlaHisGlnAspLysLeuGlnHisGlySerLysAspIlePheSerThrGlnAspGluLeu -

FIG.1a

2/9

261: LeuValTyrAsnLysAsnGlnHisGlnThrLysAsnLeuAsnGlnAspGlnGlnHisGly -
CS#3
281: ArgLysAlaAsnLysIleSerTyrGln|SerSerSerThrGluGluArgArgLeuHisTyr -
CS#4
301: GlyGluAsnGlyValGlnLysAspValSerGlnSerSerIleTyrSer|GlnThrGluGlu -
321: LysAlaGlnGlyLysSerGlnLysGlnIleThrIleProSerGlnGluGlnGluHisSer -
CS#1
341: GlnLysAlaAsnLysIleSerTyrGln|SerSerSerThrGluGluArgArgLeuHisTyr -
CS#2
361: GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyrSer|GlnThrGluLys -
381: LeuValAlaGlyLysSerGlnIleGlnAlaProAsnProLysGlnGluProTrpHisGly -
401: GluAsnAlaLysGlyGluSerGlyGlnSerThrAsnArgGluGlnAspLeuLeuSerHis -
421: GluGlnLysGlyArgHisGlnHisGlySerHisGlyGlyLeuAspIleValIleIleGlu -
441: GlnGluAspAspSerAspArgHisLeuAlaGlnHisLeuAsnAsnAspArgAsnProLeu -
461: PheThr -

FIG.1b

SUBSTITUTE SHEET (RULE 26)

		<u>PERCENT PEPTIDE HYDROLYSIS</u>					
		<u>TIME OF INCUBATION (HOURS)</u>					
PEPTIDE		0.5	1	2	3	4	20
1. SYQSSSTE		ND	0	ND	0	ND	0
2. ISYQSSSTE		ND	0	ND	0	ND	0
3. KISYQSSSTE		ND	10	ND	30	ND	90
4. NKISYQSSSTE		ND	30	ND	70	ND	100
5. NKISYQSSST		ND	20	30	ND	ND	100
6. ANKISYQSSSTE		15	25	ND	ND	80	100
7. ANKISYQSSS		4	6	16	30	45	ND
8. NKISYQSSS		2	6	22	44	55	ND
9. ANKISYQSS		1	ND	12	ND	39	ND
10 GRKANKISYQS- SSTEERRLHYGEN G		20	50	ND	ND	90	100

FIG.2

4/9


PEPTIDE	SEQ. ID. NO.	% PEPTIDE CLEAVED AT 4 HOURS
		BY YORK PSA
SEMENOGELIN (463 aa)		100 (30 min)
GRKANKISYQ-SSSTEERRLHYGENG	6	100 (2 hrs)
SQKANKISYQ-SSSTEERRLHYGENG	67	100 (3hrs)
ANKISYQ-SSSTE	11	98
ISYQ-SSST	68	0
NKISYQ-SSST	10	62
NKISYQ-SSSTE	3	90
KISYQ-SSSTE	9	49
SYQ-SSSTE	7	0 (3 hrs)
ISYQ-SSSTE	8	0
NKISYQ-SSS	17	55
ANKISYQ-SSS	18	45
ANKISYQ-SS	69	39
ANKISYQ-SSSTE-amide	11	43
Ac-ANKISYQ-SSSTL	70	57
Ac-ANKISYQ-SSSTE-amide	11	40
Ac-ANKISYQ-SSSTL-amide	70	46
Ac-ANGISYQ-SSSTE-amide	71	0
Ac-ANPISYQ-SSSTE-amide	72	0
Ac-ANKISYQ-SASTE-amide	73	66
Ac-ANKISYQ-SSKTE-amide	74	80
Ac-ANKISYQ-SSTE-amide	75	44
Ac-ANKI(dS)YQ-SSSTE-amide	76	9
Ac-ANK(dI)SYQ-SSSTE-amide	77	0
Ac-ANKISYQ-SSQTE-amide	78	55
Ac-ANKISYQ-SAKTE-amide	79	80
Ac-AN(dK)ISYQ-SSSTE-amide	80	3
Ac-ANKISYQ-SSTE-amide	81	28
Ac-ANKIYQ-SSTE-amide	82	0
Ac-ANKSYQ-SSTE-amide	83	10
Ac-ANKASYQ-SASTE-amide	84	98
Ac-ANEISYQ-SASTE-amide	85	10
Ac-NKISYQ-SS-amide	16	30
Ac-KISYQ-SS-amide	86	15
Ac-SYQ-SSTE-amide	87	65
Ac-SYQ-SSSTL-acid	88	83
Ac-ASYQ-SSTE-amide	89	68
Ac-EISYQ-SSSTE-amide	90	0
Ac-ANEISYQ-SSSTE-amide	91	0
Ac-ANKISYY-SSSTE-amide	92	73
Ac-ANKISYY-SASTE-amide	93	91

FIG.3a

SUBSTITUTE SHEET (RULE 26)

PEPTIDE	L-NUMBER	% PEPTIDE CLEAVED AT 4 HOURS BY YORK PSA
Ac-ASYQ-SSL-acid	94	71
Ac-ANSYQ-SSSTE-amide	95	28
Ac-ASYQ-SSSTE-amide	96	64
Ac-SYQ-SSSTE-amide	97	50
Ac-ANKASYQ-SASC-amide	98	78
Ac-Q-SSTE-amide	99	0
Ac-YQ-SSTE-amide	100	0
Ac-SQ-SSTE-amide	101	0
Ac-ANKISQ-SSTE-amide	102	0
Ac-AN(ORN)ISYQ-SSTE-amide	103	34
Ac-S(3PAL)Q-SSTE-amide	104	4
Ac-S(3,4-C12F)Q-SSTE-amide	105	6
Ac-SKQ-SSTE-amide	106	0
Ac-SYQ-SSTL-acid	88	81
Ac-SYQ-SSSL-acid	107	98
(e-ACA)-YQ-SSSL-amide	108	0
ANK(N-Me-I)SYQ-SSTE-amide	109	0
SYQ-SSTE-amide	110	0
HO(CH ₂) ₂ CO-YQ-SSTE-amide	111	0
Ac-SYK-SSTE-amide	112	5
Ac-SYY-SSTE-amide	113	93
Ac-SYQ-SSL-NHNH ₂	114	32
Ac-SYQ-SSL-acid	115	72
DAP-YQ-SSSL-amide	116	0

FIG.3b



DOXORUBICIN-CONGENER	SEQ.ID.NO	% PEPTIDE CLEAVED AT 4 HOURS BY YORK PSA
Ac-ANKISYQ-SSST-DOX (3')	117	20(1 hr) NO SAMPLE LEFT
Ac-ANKISYQ-SSSTL-DOX (3')	70	87
Ac-ANKASYQ-SASTL-DOX (3')	118	NA
Ac-ANKASYQ-SASL-DOX (3')	119	100 (3 hr)
Ac-ANKASYQ-SSSL-DOX (3')	120	100 (3 hrs)
Ac-ANKASYQ-SSL-DOX (3')	121	91
Ac-SYQ-SST(dL)-DOX (3')	122	17
Ac-SYQ-SSSL-DOX (3')	107	95 (PARTIALLY SOLUBLE)
Ac-ANKASYA-SSSL-DOX (3')	123	0
Ac-KYQ-SSSL-DOX (3')	124	98 (PARTIALLY SOLUBLE)
Ac-SYQ-SSKL-DOX (3')	125	88
Ac-SYQ-SSK(dL)-DOX (3')	126	87

FIG.5

8/9

DOXORUBICIN-CONGENER	SEQ. ID. NO	% PEPTIDE CLEAVED/ LNCOP MEDIA 4 HR	% PEPTIDE CLEAVED/ DUPRO MEDIA 4 HR
Ac-ANKASYQ-SASL-DOX (3')	119	92	13
Ac-ANKASYQ-SSSL-DOX (3')	121	98	13
Ac-ANKASYQ-SSSL-DOX (3')	122	95	27
Ac-SYQ-SSSL-DOX (3')	107	63	0

FIG.6

DOXORUBICIN-CONGENER	SEQ.ID.NO	LNCaP CELL KILL EC50 (μ M)
Ac-ANKISYQ-SSST-DOX (3')	117	> 100
Ac-ANKISYQ-SSSTL-DOX (3')	70	8.4
Ac-ANKASYQ-SASTL-DOX (3')	118	31
Ac-ANKASYQ-SASL-DOX (3')	119	16 (DuPRO > 100)
Ac-ANKASYQ-SSSL-DOX (3')	120	15
Ac-ANKASYQ-SSL-DOX (3')	121	6.5 (DuPRO = 117)
Ac-SYQ-SSSL-DOX (3')	107	20 (DuPRO > 100) (PARTIALLY SOLUBLE)
Ac-ANKASYA-SSSL-DOX (3')	123	> 100
Ac-KYQ-SSSL-DOX (3')	124	6.5 (DuPRO > 100)
Ac-SYQ-SSKL-DOX (3')	125	11.8 (DuPRO > 100)
Ac-SYQ-SSK(dL)-DOX (3')	126	>100 (DuPRO > 100)
Ac-hRYQ-SSSL-DOX (3')	145	6.4 (DuPRO > 100)
Ac-KYQ-SSS(NIe)-DOX (3')	146	4.4 (DuPRO > 100)

FIG.7

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/08156

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A16K 38/00; C07K 1/00, 7/06 7/08, 7/10; C12Q 1/00, 1/37;
US CL :530/324,325326,327,328 ,402; 435/1+; 514/12,13,14,15,16,17
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/324,325326,32,328 ,402; 435/1+; 514/12,13,14,15,16,17

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
CAS, STN, APS

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Journal of Biological Chemistry, Volume 264, No.3, issued 25 January 1989, Lilja et al, "Semenogelin, the Predominant Protein in Human Semen, pages 1894-1900.	1-7
X	Proceedings of the the National Academy of Sciences, Vol.89, issued May 1992, Lilja et al, " Molecular cloning of epididymal and seminal vesicular transcripts encoding a semenogelin-related protein", pages 4559-4563.	1-7
Y	WO , A, 94/10343, (CROCE ET AL) 11 May 1994, see entire document.	8-11

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
05 OCTOBER 1995

Date of mailing of the international search report
01 NOV 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

S.G. Marshall

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/08156

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A, 92/01936, (LILJA ET AL) 06 Febuary 1992, see entire document.	8-11
Y,P	US, A, 5,349,066, (KANEKO ET AL), 20 September 1994, see entire document.	12-20
Y,P	US, A, 5,391,723 (PRIEST) 21 February 1995, see entire document.	12-20

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/08156

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/08156

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

- Group I, claims 1-7, drawn to oligopeptides.
- Group II, claims 8-11, drawn to assay.
- Group III, claims 12-20, drawn to conjugate.

The inventions listed as Groups I, II, and III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The invention of group I relates to oligopeptides while the invention of group II relates to an assay. The inventions of group I and group III do not share a special technical feature with group II, because group I and group III can be used in a different process, such as in a method of treating prostate cancer, instead of in an assay method. Additionally, group I does not share a common technical feature with the invention of group III because the two inventions differ structurally.